[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 316
1. Sakurada K, Saino M, Mouri W, Sato A, Kitanaka C, Kayama T: Nestin expression in central nervous system germ cell tumors. Neurosurg Rev; 2008 Apr;31(2):173-6; discussion 176-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in central nervous system germ cell tumors.
  • Central nervous system (CNS) germ cell tumors constitute a unique class of rare tumors that mainly affect children and adolescents.
  • These tumors are believed to originate from displaced primordial germ cells.
  • Recently, results of treatment of germ cell tumors have improved with use of radiotherapy and combination chemotherapy.
  • However, some tumors have proven refractory to intensive treatment with surgery, radiation, and combination chemotherapy.
  • Nestin is an intermediate filament protein expressed in undifferentiated cells during CNS development and in CNS tumors and is used as a marker of immature elements of tumors, including brain tumor stem cells.
  • In this study, we examined for the first time nestin expression in 19 CNS germ cell tumors (nine pure germinomas, five germinomas with syncytiotrophoblastic giant cells, one yolk sac tumor, one choriocarcinoma, one embryonal carcinoma, and two mature teratomas).
  • Clinically, nestin-negative tumors did not exhibit dissemination, while all tumors that exhibited dissemination also strongly expressed nestin protein.
  • These findings suggest that the detection of nestin expression could be useful in the management of CNS germ cell tumors, as an auxiliary predictor of dissemination and/or progression.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Central Nervous System Neoplasms / genetics. Intermediate Filament Proteins / biosynthesis. Intermediate Filament Proteins / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Nerve Tissue Proteins / biosynthesis. Nerve Tissue Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Choriocarcinoma / genetics. Choriocarcinoma / metabolism. Choriocarcinoma / pathology. Endodermal Sinus Tumor / genetics. Endodermal Sinus Tumor / metabolism. Endodermal Sinus Tumor / pathology. Female. Germinoma / genetics. Germinoma / metabolism. Germinoma / pathology. Giant Cell Tumors / genetics. Giant Cell Tumors / metabolism. Giant Cell Tumors / pathology. Humans. Hypopituitarism / etiology. Immunoenzyme Techniques. Magnetic Resonance Imaging. Male. Nestin. Teratoma / genetics. Teratoma / metabolism. Teratoma / pathology. Vision Disorders / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1999 Feb;90(2):258-64 [9950496.001]
  • [Cites] Cell Mol Life Sci. 2004 Oct;61(19-20):2510-22 [15526158.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):222-3 [15677549.001]
  • [Cites] APMIS. 2002 Jun;110(6):499-507 [12193211.001]
  • [Cites] Neurosci Lett. 2006 May 29;400(1-2):80-5 [16529857.001]
  • [Cites] Neurosurg Focus. 1998 Jul 15;5(1):e7 [17140188.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):147-58 [11799134.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Mol Cancer. 2006 Dec 02;5:67 [17140455.001]
  • [Cites] Neurol Res. 1989 Jun;11(2):118-26 [2569683.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6 [14711994.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):311-6 [11767296.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • (PMID = 18092184.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


2. Propp JM, McCarthy BJ, Davis FG, Preston-Martin S: Descriptive epidemiology of vestibular schwannomas. Neuro Oncol; 2006 Jan;8(1):1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vestibular schwannomas, commonly termed acoustic neuromas, arise from the vestibular branch of the eighth cranial nerve (acoustic nerve) and are benign, slow-growing brain tumors that negatively impact patient quality of life.
  • They are thought to account for the majority of intracranial nerve sheath tumors.
  • To describe incidence rate patterns and trends of primary nerve sheath tumors of the brain/CNS and the subset of vestibular schwannomas in two population-based incidence registries, data were obtained from 11 Central Brain Tumor Registry of the United States (CBTRUS) collaborating state registries and the Los Angeles County Cancer Surveillance Program (LACCSP) (1975-1998).
  • Multiplicative Poisson regression models were used to compare trends in primary nerve sheath tumors of the brain/CNS overall and in subgroups, including vestibular schwannomas, controlling for age, gender, race, microscopic confirmation, and region.
  • The overall incidence of primary nerve sheath tumors of the brain/CNS was 1.1 per 100,000 person-years (CBTRUS, 1995-1999 and LACCSP, 1995-1998).
  • Moreover, the incidence of primary nerve sheath tumors of the brain/CNS overall (CBTRUS, 1985-1999 and LACCSP, 1975-1998) and of vestibular schwannomas (CBTRUS, 1992-1999 and LACCSP, 1992-1998) increased over time.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 1992 Jun 15;135(12):1349-57 [1510081.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 18;84(6):442-5 [1538422.001]
  • [Cites] Ann Neurol. 1995 Jan;37(1):67-73 [7818260.001]
  • [Cites] Laryngoscope. 1999 May;109(5):736-40 [10334223.001]
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] Am J Otol. 2000 Sep;21(5):690-4 [10993460.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):203-7 [11158188.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):141-51 [11465394.001]
  • [Cites] Neurology. 2002 Apr 23;58(8):1304-6 [11971109.001]
  • [Cites] Neuroepidemiology. 2003 Mar-Apr;22(2):124-9 [12629278.001]
  • [Cites] Am J Epidemiol. 2004 Feb 1;159(3):277-83 [14742288.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2004 Sep-Oct;7(5):351-84 [15371240.001]
  • [Cites] Epidemiology. 2004 Nov;15(6):653-9 [15475713.001]
  • [Cites] Health Care Financ Rev. 1984 Winter;6(2):1-29 [10310949.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Br J Cancer. 1989 May;59(5):783-6 [2736213.001]
  • [Cites] Neuroepidemiology. 1989;8(6):283-95 [2586698.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1300-6 [1739929.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • (PMID = 16443943.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1871924
  •  go-up   go-down


3. Gill P, Litzow M, Buckner J, Arndt C, Moynihan T, Christianson T, Ansell S, Galanis E: High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Cancer; 2008 Apr 15;112(8):1805-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
  • BACKGROUND: Embryonal central nervous system (CNS) tumors (medulloblastoma, cerebral neuroblastoma, pineoblastoma, and primitive neuroectodermal tumors) are rare in adults.
  • The purpose of the current study was to evaluate adult patients with embryonal CNS tumors who were treated with HDC with ASCT and compare their outcomes with those of patients who received conventional-dose chemotherapy.
  • METHODS: The authors reviewed the medical records of 23 adult patients (age >or= 18 years) who were treated at the Mayo Clinic for recurrent embryonal CNS tumors between 1976 and 2004.
  • CONCLUSIONS: Improvements in the median TTP and survival noted with the administration of HDC with ASCT, as well as the acceptable toxicity of this regimen, supports consideration of its use in adults with recurrent embryonal CNS tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Medulloblastoma / drug therapy. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carmustine / administration & dosage. Cisplatin / administration & dosage. Cohort Studies. Disease Progression. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Retrospective Studies. Survival Rate. Thiotepa / administration & dosage. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2008 Apr 15;112(8):1643-5 [18306390.001]
  • (PMID = 18300237.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 35S93Y190K / Procarbazine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 905Z5W3GKH / Thiotepa; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


Advertisement
4. Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, Rivera E: Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer; 2007 Dec 15;110(12):2640-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis.
  • BACKGROUND: Breast cancer is the second most common cause of central nervous system (CNS) metastases.
  • Several risk factors for CNS metastases have been reported.
  • The objective of the current study was to describe clinicopathologic characteristics and prognostic factors in breast cancer patients with CNS metastases.
  • METHODS: The authors retrospectively evaluated clinical data from 420 patients who had been diagnosed with breast cancer and CNS metastasis between 1994 and 2004 at the University of Texas M. D.
  • Most patients had invasive ductal histology (91.2%), grade 3 tumors (81.4%) (using the modified Black nuclear grading system), T2 tumor classification (40.1%), and N1 lymph node status (59.7%) diagnosis.
  • CNS metastasis was the site of first recurrence in 53 patients (12%).
  • The median time from breast cancer diagnosis to CNS metastasis was 30.9 months (range, from -5 months to 216.7 months).
  • The median follow-up after a diagnosis of CNS metastasis was 6 months (range, 7-95.9 months).
  • CONCLUSIONS: The current results indicated that the prognosis remains patients with breast cancer metastatic to the CNS.
  • More effective treatment approaches are needed for patients with CNS metastases, even for those with favorable prognostic factors, such as ER-positive tumors or younger age.
  • [MeSH-major] Breast Neoplasms / pathology. Central Nervous System Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Time Factors


5. Torres P, Galán Y, Lence J, García M, Lezcano M, Fernández L: Childhood cancer incidence in Cuba, 2001 to 2003. MEDICC Rev; 2010;12(2):19-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The International Classification of Childhood Cancer (ICCC) is currently recommended for registering neoplasms in the population aged < or =19 years.
  • AARs for leukemias, lymphomas and central nervous system (CNS) tumors were used to analyze childhood cancer risk by sex and geographical distribution in the country's 14 provinces and Isle of Youth Special Municipality.
  • Leukemias, lymphomas and central nervous system tumors comprised 61.1% of new cases, and geographic distribution of these diagnostic groups varied by sex.
  • [MeSH-major] Neoplasms / epidemiology. Registries
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Cuba / epidemiology. Female. Humans. Incidence. Infant. International Classification of Diseases. Male. Risk Factors. Sex Factors. Young Adult


6. Fassett DR, Pingree J, Kestle JR: The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature. J Neurosurg; 2005 Jan;102(1 Suppl):59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature.
  • Myxopapillary ependymomas (MPEs) have historically been thought to be benign tumors occurring most frequently in adults.
  • Only 8 to 20% of these tumors occur in the first two decades of life, making this tumor a rarity in pediatric neurosurgery.
  • Four (80%) of these five patients suffered from disseminated disease of the central nervous system (CNS) at the time of presentation; this incidence is much higher than that reported in the combined adult and pediatric literature.
  • In nine cases (35%) CNS metastases occurred.
  • In those cases in which patients underwent screening for CNS tumor dissemination, however, the incidence of disseminated disease was 58% (seven of 12 patients).
  • In pediatric patients MPEs may spread throughout the CNS via cerebrospinal fluid pathways; therefore, MR imaging of the entire CNS axis is recommended at both presentation and follow-up review to detect tumor dissemination.
  • [MeSH-major] Brain Neoplasms / secondary. Ependymoma / pathology. Ependymoma / secondary. Neoplasm Metastasis. Spinal Cord Neoplasms / pathology


7. Kieran MW, Walker D, Frappaz D, Prados M: Brain tumors: from childhood through adolescence into adulthood. J Clin Oncol; 2010 Nov 10;28(32):4783-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumors: from childhood through adolescence into adulthood.
  • Clinical care is currently divided into adult or pediatric care; adolescent patients require specific expertise that most clinical practices do not have.
  • When illness coincides with the adolescent transition, the health system is severely challenged.
  • Health systems historically have varied widely in the age they choose for allocating an individual to the adult model of health care.
  • Tumors of the CNS complicate the difficult adjustments required in adolescents and young adults by virtue of their morbidity, complex treatment, and prognosis.
  • Some brain tumors are unique to children, some occur predominantly in adults, and others peak in adolescence.
  • Delays in the diagnosis of brain tumors can occur at any age but are particularly common in adolescence because of difficulties of accessing health systems, the difficulties of discriminating pathologic from typical adolescent behavioral characteristics, and changing endocrine function.
  • This article will discuss the changing brain tumor profile of children, adolescents, and adults, with a focus on our limited understanding of the adolescent/young adult transition period.
  • [MeSH-major] Brain Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adolescent Medicine. Adult. Brain / growth & development. Child. Continuity of Patient Care. Glioma / diagnosis. Glioma / therapy. Humans. Medulloblastoma / diagnosis. Medulloblastoma / therapy. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458039.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


8. Wang ZH, Shi HY, Wang ZB: [Metastatic alveolar soft tissue sarcoma of the central nervous system: a clinicopathological analysis of four cases]. Ai Zheng; 2009 Nov;28(11):1214-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic alveolar soft tissue sarcoma of the central nervous system: a clinicopathological analysis of four cases].
  • BACKGROUND AND OBJECTIVE: Metastatic alveolar soft tissue sarcoma (ASTS) of the central nervous system is rare and is easy to be misdiagnosed as other primary tumors of central nervous system.
  • This study was to analyze the clinical and pathological features of four patients with ASTS of the central nervous system and to clarify their differential diagnosis as well as prognosis.
  • The tumor cells had clear or eosinophilic cytoplasm and prominent nucleoli, arranged in alveolar structures, which were surrounded by delicate blood sinuses.
  • CONCLUSION: ASTS of the central nervous system was mostly metastatic and should be differentiated from other CNS tumors such as meningioma, melonocytic tumor, rhabdomyosarcoma and paraganglioma.
  • Metastatic ASTS of the central nervous system had poor prognosis and the five-year survival rate was low.
  • [MeSH-major] Cranial Fossa, Posterior. Sarcoma, Alveolar Soft Part / pathology. Sarcoma, Alveolar Soft Part / secondary. Skull Base Neoplasms / pathology. Skull Base Neoplasms / secondary
  • [MeSH-minor] Actins / metabolism. Adult. Desmin / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasm Recurrence, Local. Paraganglioma / diagnosis. Prognosis. Rhabdomyosarcoma / diagnosis. S100 Proteins / metabolism. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895745.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / S100 Proteins
  •  go-up   go-down


9. Sheedy SP, Welker KM, DeLone DR, Gilbertson JR: CNS metastases of carcinoma ex pleomorphic adenoma of the parotid gland. AJNR Am J Neuroradiol; 2006 Aug;27(7):1483-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS metastases of carcinoma ex pleomorphic adenoma of the parotid gland.
  • Pleomorphic adenomas (PAs), also known as benign mixed tumors, are common tumors of the parotid gland.
  • These tumors occasionally undergo malignant transformation, with potentially devastating consequences.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma, Pleomorphic / pathology. Brain Neoplasms / secondary. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908563.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Lesniak MS: Gene therapy for malignant glioma. Expert Rev Neurother; 2006 Apr;6(4):479-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme represents the most common primary malignant tumor of the adult CNS.
  • Consequently, efforts aimed at developing new therapies have focused on new treatment strategies that specifically target tumor cells and spare normal cells.
  • One such modality, gene therapy, has shown promise in the spectrum of agents utilized against brain tumors.
  • This review highlights the principles of gene therapy and discusses the results of recent clinical trials in which gene therapy has been employed against malignant brain tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Genetic Therapy / methods. Glioma / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623647.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 77
  •  go-up   go-down


11. Yoo KH, Lee SH, Lee J, Sung KW, Jung HL, Koo HH, Lim DH, Kim JH, Shin HJ: Improved outcome of central nervous system germ cell tumors: implications for the role of risk-adapted intensive chemotherapy. J Korean Med Sci; 2010 Mar;25(3):458-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome of central nervous system germ cell tumors: implications for the role of risk-adapted intensive chemotherapy.
  • To determine the impact of treatment protocols on the outcome of central nervous system germ cell tumors (CNS-GCTs), we reviewed the medical records of 53 patients who received front-line chemotherapy from September 1997 to September 2006.
  • Our data suggest that risk-adapted intensive chemotherapy may improve the outcome of patients with malignant CNS-GCTs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / therapy. Radiotherapy
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / metabolism. Child. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Risk Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1995 Mar;36(3):459-64; discussion 464-6 [7538635.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2908-15 [8918487.001]
  • [Cites] J Neurooncol. 1997 Mar;32(1):71-80 [9049865.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):419-26 [9308946.001]
  • [Cites] J Neurooncol. 1998 May;37(3):229-39 [9524081.001]
  • [Cites] Scand Audiol. 1999;28(3):139-43 [10489862.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2156-67 [16220552.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):285-91 [16598761.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2585-92 [10561326.001]
  • [Cites] Oncologist. 2000;5(4):312-20 [10964999.001]
  • [Cites] Childs Nerv Syst. 2002 Feb;18(1-2):30-7 [11935241.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):369-76 [12872359.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Sep;43 Suppl:i-vii, 1-111 [14705327.001]
  • [Cites] Radiology. 1978 Sep;128(3):745-51 [674649.001]
  • [Cites] Med Pediatr Oncol. 1981;9(4):361-5 [6167845.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):932-40 [2981605.001]
  • [Cites] J Neurooncol. 1985;3(2):147-52 [3897472.001]
  • [Cites] Acta Oncol. 1988;27(1):43-50 [2835067.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):285-90 [3403311.001]
  • [Cites] J Neurosurg. 1989 May;70(5):676-81 [2540291.001]
  • [Cites] Neurol Res. 1989 Jun;11(2):118-26 [2569683.001]
  • [Cites] Pharmacol Toxicol. 1992 Feb;70(2):143-7 [1508841.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):943-9 [7607968.001]
  • [Cites] Radiother Oncol. 1996 Jan;38(1):19-23 [8850422.001]
  • (PMID = 20191048.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2826748
  • [Keywords] NOTNLM ; Central Nervous System / Drug Therapy / Neoplasms, Germ Cell and Embryonal / Survival
  •  go-up   go-down


12. Bavaresco L, Bernardi A, Braganhol E, Wink MR, Battastini AM: Dexamethasone inhibits proliferation and stimulates ecto-5'-nucleotidase/CD73 activity in C6 rat glioma cell line. J Neurooncol; 2007 Aug;84(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas are the most common and devastating primary tumors of the adult central nervous system.
  • Dexamethasone, a synthetic glucocorticoid, is commonly co-administered to control edema in the management of brain tumors during chemotherapy and radiotherapy.
  • [MeSH-major] 5'-Nucleotidase / metabolism. Anti-Inflammatory Agents / pharmacology. Brain Neoplasms / enzymology. Dexamethasone / pharmacology. Glioma / enzymology
  • [MeSH-minor] Adenosine Monophosphate / metabolism. Animals. Cell Death / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Protein Kinase C / metabolism. Purines / metabolism. Rats. Signal Transduction / drug effects. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. ADENOSINE 5'-PHOSPHATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):805-9 [8687132.001]
  • [Cites] Anal Biochem. 1986 Sep;157(2):375-80 [2946250.001]
  • [Cites] Am J Reprod Immunol. 2005 Mar;53(3):144-52 [15727569.001]
  • [Cites] Vascul Pharmacol. 2005 Mar;42(4):153-62 [15820441.001]
  • [Cites] J Cell Physiol. 2001 Jan;186(1):19-23 [11147810.001]
  • [Cites] J Neurooncol. 2001 Jan;51(2):105-10 [11386406.001]
  • [Cites] Science. 1968 Jul 26;161(3839):370-1 [4873531.001]
  • [Cites] Drug Metab Dispos. 2006 Jun;34(6):1063-9 [16531474.001]
  • [Cites] Pharmacol Rev. 1998 Sep;50(3):413-92 [9755289.001]
  • [Cites] Pharmacol Ther. 2003 Oct;100(1):31-48 [14550503.001]
  • [Cites] Neurology. 1997 Jun;48(6):1704-9 [9191791.001]
  • [Cites] Purinergic Signal. 2006 Jun;2(2):409-30 [18404480.001]
  • [Cites] Anticancer Res. 1994 Jul-Aug;14(4A):1585-8 [7979189.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Dec;92(5):375-82 [15698542.001]
  • [Cites] Eur J Pharmacol. 1992 Oct 1;227(2):113-22 [1426027.001]
  • [Cites] Br J Pharmacol. 1997 Jan;120(2):273-81 [9117120.001]
  • [Cites] J Pharmacol Toxicol Methods. 2005 Sep-Oct;52(2):234-43 [16125621.001]
  • [Cites] Genes Dev. 1995 Jul 1;9(13):1608-21 [7628695.001]
  • [Cites] Neuroscience. 2000;96(2):417-25 [10683582.001]
  • [Cites] Cell Tissue Res. 2002 Dec;310(3):257-70 [12457224.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4472-8 [12947007.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Jan;280(1):R25-32 [11124130.001]
  • [Cites] Oncogene. 1998 Sep 24;17(12):1567-75 [9794234.001]
  • [Cites] Trends Pharmacol Sci. 2006 Mar;27(3):166-76 [16487603.001]
  • [Cites] Apoptosis. 1999 Jun;4(3):197-211 [14634282.001]
  • [Cites] Melanoma Res. 2006 Jun;16(3):213-22 [16718268.001]
  • [Cites] BMC Cancer. 2006 Sep 23;6:226 [16995949.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Trends Pharmacol Sci. 2006 Apr;27(4):211-7 [16530853.001]
  • [Cites] Nucleic Acids Res. 1992 Feb 25;20(4):825-9 [1531873.001]
  • [Cites] Cancer Lett. 2003 Aug 20;198(2):211-8 [12957360.001]
  • [Cites] Biochem J. 1992 Jul 15;285 ( Pt 2):345-65 [1637327.001]
  • (PMID = 17453149.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Purines; 415SHH325A / Adenosine Monophosphate; 7S5I7G3JQL / Dexamethasone; EC 2.7.11.13 / Protein Kinase C; EC 3.1.3.5 / 5'-Nucleotidase
  •  go-up   go-down


13. Teng FY, Tang BL: No go for brain tumors? J Mol Neurosci; 2005;25(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No go for brain tumors?
  • The Nogo gene and its products are well known as adult central nervous system (CNS) myelin inhibitors of neuronal regeneration.
  • We review here experimental findings that might link Nogo to CNS malignancy.
  • On the other hand, extracellular domains of Nogo might inhibit the migration and invasion of CNS tumors.
  • Depending on the physiological context, Nogo isoforms might therefore be antitumorigenic or have tumor-suppressing activities.
  • [MeSH-major] Antineoplastic Agents / metabolism. Brain Neoplasms / genetics. Growth Inhibitors. Myelin Proteins
  • [MeSH-minor] Central Nervous System / pathology. Central Nervous System / physiology. Humans. Nogo Proteins. Protein Isoforms / genetics. Protein Isoforms / metabolism. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2002 Jul 1;22(13):5505-15 [12097502.001]
  • [Cites] J Neurosci. 2002 May 1;22(9):3553-67 [11978832.001]
  • [Cites] Nat Med. 2004 Apr;10 (4):382-8 [15034570.001]
  • [Cites] Br J Cancer. 1998 Dec;78(12):1564-72 [9862565.001]
  • [Cites] Nat Neurosci. 2004 Mar;7(3):221-8 [14966521.001]
  • [Cites] Neuron. 2002 Jul 18;35(2):283-90 [12160746.001]
  • [Cites] J Neurosci. 2003 Jul 2;23 (13):5393-406 [12843238.001]
  • [Cites] J Cell Biol. 1999 Jan 25;144(2):373-84 [9922462.001]
  • [Cites] Oncogene. 2001 Jul 5;20(30):3929-36 [11494121.001]
  • [Cites] Nature. 2002 Nov 7;420(6911):74-8 [12422217.001]
  • [Cites] Nat Neurosci. 2002 Dec;5(12 ):1302-8 [12426574.001]
  • [Cites] Neuron. 2003 Apr 24;38(2):213-24 [12718856.001]
  • [Cites] Nature. 2000 Jan 27;403(6768):434-9 [10667796.001]
  • [Cites] Nature. 2000 Jan 27;403(6768):439-44 [10667797.001]
  • [Cites] Neuron. 2003 Apr 24;38(2):201-11 [12718855.001]
  • [Cites] Neuron. 1988 Mar;1(1):85-96 [3272156.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):149-58 [9426071.001]
  • [Cites] Nature. 2000 Jan 27;403(6768):383-4 [10667780.001]
  • [Cites] J Neurosci. 2002 Dec 1;22(23 ):10368-76 [12451136.001]
  • [Cites] J Neurochem. 2004 Sep;90(5):1156-62 [15312170.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1390-9 [12618765.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5736-46 [11126360.001]
  • [Cites] Neurobiol Dis. 2002 Aug;10 (3):358-65 [12270696.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):941-4 [12068310.001]
  • [Cites] Mol Cell Neurosci. 2003 Dec;24(4):1083-102 [14697671.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):2977-87 [15021917.001]
  • [Cites] Neuron. 2003 Apr 24;38(2):187-99 [12718854.001]
  • [Cites] Neurosci Lett. 2002 Aug 16;328(3):257-60 [12147320.001]
  • [Cites] J Neurosci Res. 2002 Mar 1;67(5):559-65 [11891768.001]
  • [Cites] Nature. 2001 Jan 18;409(6818):341-6 [11201742.001]
  • [Cites] Invest New Drugs. 2004 Jan;22(1):27-37 [14707492.001]
  • [Cites] Apoptosis. 2003 Jan;8(1):5-9 [12510146.001]
  • (PMID = 15781961.001).
  • [ISSN] 0895-8696
  • [Journal-full-title] Journal of molecular neuroscience : MN
  • [ISO-abbreviation] J. Mol. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Growth Inhibitors; 0 / Myelin Proteins; 0 / Nogo Proteins; 0 / Protein Isoforms; 0 / Proto-Oncogene Proteins; 0 / RTN4 protein, human
  • [Number-of-references] 32
  •  go-up   go-down


14. Ebert S, Phillips DJ, Jenzewski P, Nau R, O'Connor AE, Michel U: Activin A concentrations in human cerebrospinal fluid are age-dependent and elevated in meningitis. J Neurol Sci; 2006 Dec 1;250(1-2):50-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Activin A, and its binding protein, follistatin (FS), are expressed in the central nervous system (CNS).
  • Activin A concentrations in CSF of patients with various neurological diseases, including meningitis, chronic inflammatory CNS diseases, neurodegenerative diseases, tumors in the CNS, cerebral ischemia, intracerebral/subarachnoid hemorrhages, subdural hemorrhages and epileptic seizures, were compared with age- and sex-matched control patients.
  • The latter underlines a role for activin A in acute inflammatory processes within the CNS.
  • [MeSH-minor] Adult. Aged. Biomarkers / cerebrospinal fluid. Central Nervous System / metabolism. Central Nervous System / microbiology. Central Nervous System / physiopathology. Encephalitis / cerebrospinal fluid. Encephalitis / diagnosis. Encephalitis / physiopathology. Female. Follistatin / analysis. Follistatin / cerebrospinal fluid. Humans. Immunoassay. Male. Middle Aged. Predictive Value of Tests. Up-Regulation / physiology

  • MedlinePlus Health Information. consumer health - Meningitis.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920154.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cerebrospinal Fluid Proteins; 0 / Follistatin; 0 / activin A; 104625-48-1 / Activins
  •  go-up   go-down


15. Carlson ML, Babovic-Vuksanovic D, Messiaen L, Scheithauer BW, Neff BA, Link MJ: Radiation-induced rhabdomyosarcoma of the brainstem in a patient with neurofibromatosis type 2. J Neurosurg; 2010 Jan;112(1):81-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis Type 2 (NF2) is a rare autosomal dominant disorder characterized by the development of benign tumors of the peripheral nervous system and the CNS, including schwannomas, meningiomas, and ependymomas.
  • The gene responsible for the development of NF2 acts as a tumor suppressor gene.
  • Stereotactic radiotherapy (SRT) or single-fraction stereotactic radiosurgery has been increasingly used in the past decades to treat benign tumors in patients with NF2.
  • These radiotherapy methods are less invasive and can be potentially used to treat multiple tumors in a single session.
  • Few reports exist of malignant peripheral nerve sheath tumors, meningiomas, or ependymomas occurring after SRT or stereotactic radiosurgery in patients with NF2.
  • Compared with patients with sporadic tumors, NF2 patients having a germline tumor suppressor gene defect may be more prone to secondary malignancies after treatment involving radiation therapy.
  • [MeSH-major] Brain Stem Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Neurofibromatosis 2 / surgery. Radiosurgery / adverse effects. Rhabdomyosarcoma / etiology
  • [MeSH-minor] Adult. Brain Neoplasms / etiology. Brain Neoplasms / surgery. Brain Stem / pathology. Brain Stem / radiation effects. Brain Stem / surgery. Ear Neoplasms / etiology. Ear Neoplasms / surgery. Fatal Outcome. Female. Humans. Neurilemmoma / etiology. Neurilemmoma / surgery. Vestibular Diseases / etiology. Vestibular Diseases / surgery

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurosurg. 2010 Jan;112(1):209. Scheithauer, Bernd B [corrected to Scheithauer, Bernd W]
  • (PMID = 19575577.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Agrawal M, Uppin MS, Patibandla MR, Bhattacharjee S, Panigrahi MK, Saradhi V, Rani JY, Purohit AK, Challa S: Teratomas in central nervous system: a clinico-morphological study with review of literature. Neurol India; 2010 Nov-Dec;58(6):841-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Teratomas in central nervous system: a clinico-morphological study with review of literature.
  • AIMS: To study the demographic, clinico-morphological and follow-up data of central nervous system (CNS) teratomas.
  • MATERIALS AND METHODS: Cases diagnosed as mature or immature teratomas in the CNS over a 20-year period were included in the study.
  • RESULTS: A total of 14 tumors were diagnosed as teratomas.
  • Of these, 11 were mature cystic teratomas; and 1 case each, of teratoma with malignant transformation, terato-carcinoma and mixed germ cell tumor (immature teratoma with germinoma).
  • Radiologically, contrast enhancement with predominantly solid component was suggestive of malignancy or an aggressive tumor.
  • Excision was curative or provided symptomatic relief in most cases; terato-carcinoma and mixed germ cell tumor patients needed adjuvant radiotherapy.
  • CONCLUSION: CNS teratomas are rare.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / surgery. Teratoma / diagnosis. Teratoma / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150046.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  •  go-up   go-down


17. Ahuja G, Cuellar S, Choudhry I, Setty S, Yao M, Villano JL: Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy. Onkologie; 2008 Mar;31(3):119-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy.
  • INTRODUCTION: Locally advanced tumors in the olfactory area commonly have central nervous system (CNS) involvement and are often incurable.
  • CASE REPORT: We report the treatment of a 25-year-old male patient who presented with a large, neuroendocrine tumor arising from the ethmoid complex.
  • An endoscopic nasal biopsy demonstrated a poorly differentiated neuroendocrine tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / therapy. Ethmoid Bone / pathology. Neuroendocrine Tumors / therapy. Radiotherapy, Adjuvant. Skull Neoplasms / therapy
  • [MeSH-minor] Adult. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Humans. Male. Organization and Administration

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18322415.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


18. Agarwal PA, Menon S, Smruti BK, Singhal BS: Primary central nervous system lymphoma: a profile of 26 cases from Western India. Neurol India; 2009 Nov-Dec;57(6):756-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: a profile of 26 cases from Western India.
  • BACKGROUND: Primary central nervous system (CNS) lymphoma (PCNSL) is a rare malignant non-Hodgkin's lymphoma and it accounts for 1% of all intracranial tumors.
  • [MeSH-major] Central Nervous System Neoplasms. Lymphoma
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antiretroviral Therapy, Highly Active / methods. Enzyme-Linked Immunosorbent Assay / methods. Female. HIV Seropositivity / drug therapy. Humans. India / epidemiology. L-Lactate Dehydrogenase / blood. Magnetic Resonance Imaging / methods. Male. Mental Status Schedule. Middle Aged. Retrospective Studies. Treatment Outcome


19. Abe T, Kitajima T, Honma K, Kurasaki T, Okazuka K, Shibasaki Y, Momoi A, Kuroha T, Masuko M, Yagisawa K, Furukawa T, Toba K, Aizawa Y: [Effective combination chemotherapy with rituximab for acute lymphoblastic leukemia with bone relapse after bone marrow transplantation]. Rinsho Ketsueki; 2008 Nov;49(11):1556-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initially, ALL relapsed in the central nervous system (CNS) 1 year after transplantation.
  • Then, ALL relapsed as a single bone tumor involving the CNS and pelvis 4 years after transplantation.
  • Finally, multiple bone tumors in the pelvis and lumbar bones were found as well as spread to the bone marrow 5 years after transplantation.
  • Flow cytometry analyses detected CD20-positive cells in the bone tumor.
  • Though the initial bone tumor was resistant to hyper CVAD, radiation was effective and this patient achieved complete remission.
  • After the third relapse, bone marrow achieved complete remission with the administration of pirarubicin, vincristine, prednisolone, and L-asparaginase (arranged DVP-L), though this combination chemotherapy itself was not effective in multiple bone tumors.
  • Thereafter, arranged DVP-L plus rituximab was administered, which resulted in significant tumor reduction.
  • Biweekly rituximab administration as maintenance therapy has completely prevented the regrowth of bone tumors.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Bone Marrow Transplantation. Bone Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047788.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


20. Salvati M, D'Elia A, Brogna C, Frati A, Antonelli M, Giangaspero F, Raco A, Santoro A, Delfini R: Cerebral astroblastoma: analysis of six cases and critical review of treatment options. J Neurooncol; 2009 Jul;93(3):369-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Astroblastoma is one of the rarest tumors of the central nervous system (CNS), and its classification, histogenesis, diagnosis and therapeutic management are still being debated.
  • The typical histopathological appearance is the perivascular, astroblastic pseudorosette, which is however present in other CNS tumors.
  • To clarify the clinical, radiological, histopathological, prognostic and therapeutic characteristics, which have been treated only recently and are not well established yet due to the rarity of this tumor, six cases of histologically proven astroblastoma were retrospectively analyzed in light of more pertinent literature and paying special attention to therapeutic remarks.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / therapy. Neoplasms, Neuroepithelial / pathology. Neoplasms, Neuroepithelial / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgical Procedures. Radiotherapy

  • Genetic Alliance. consumer health - Astroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1985 Aug;24(2):218-22 [4012581.001]
  • [Cites] J Neurosurg. 1986 Apr;64(4):657-61 [3950749.001]
  • [Cites] Pathology. 2006 Feb;38(1):78-80 [16484017.001]
  • [Cites] Acta Neuropathol. 2016 Jun;131(6):803-20 [27157931.001]
  • [Cites] J Neurosurg. 1995 Sep;83(3):550-5 [7545227.001]
  • [Cites] J Neurooncol. 1998 Oct;40(1):59-65 [9874187.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Jul-Aug;14 (4):946-50 [8352168.001]
  • [Cites] Brain Pathol. 2000 Jul;10 (3):342-52 [10885653.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jun;146(6):629-33 [15168232.001]
  • [Cites] Comput Med Imaging Graph. 2002 May-Jun;26(3):187-91 [11918982.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Feb;23(2):243-7 [11847049.001]
  • [Cites] Surg Neurol. 1991 Feb;35(2):116-21 [1990478.001]
  • [Cites] Ultrastruct Pathol. 1999 Sep-Oct;23(5):325-32 [10582270.001]
  • [Cites] Neuropathology. 2000 Sep;20(3):228-32 [11132940.001]
  • [Cites] Clin Neurol Neurosurg. 1975;78(2):89-98 [1222508.001]
  • [Cites] Neurosurgery. 1989 Jul;25(1):6-13 [2755581.001]
  • [Cites] Acta Neuropathol. 1986;70(1):10-6 [3727930.001]
  • [Cites] J Neuroradiol. 1996 Jun;23(1):38-40 [8767917.001]
  • [Cites] Pediatr Pathol. 1993 May-Jun;13(3):323-32 [8516227.001]
  • [Cites] Acta Neuropathol. 1989;78(5):472-83 [2683559.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):745-50 [3967170.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Apr;15(4):199-205 [8703845.001]
  • (PMID = 19214707.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


21. Rasmussen A, Nava-Salazar S, Yescas P, Alonso E, Revuelta R, Ortiz I, Canizales-Quinteros S, Tusié-Luna MT, López-López M: Von Hippel-Lindau disease germline mutations in Mexican patients with cerebellar hemangioblastoma. J Neurosurg; 2006 Mar;104(3):389-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Central nervous system (CNS) hemangioblastomas are benign vascular tumors arising either sporadically or as a manifestation of von Hippel-Lindau (VHL) disease, a hereditary cancer syndrome.
  • The authors studied a series of patients with CNS hemangioblastomas and their families to identify germline mutations in the VHL tumor suppressor gene and to establish a predictive testing and screening protocol.
  • All asymptomatic mutation carriers underwent genetic counseling and tumor surveillance.
  • Seven of the families had definite clinical criteria of VHL disease, five had sporadic hemangioblastoma, and four had CNS hemangioblastoma combined with minor visceral signs.
  • CONCLUSIONS: Genetic testing for mutations in the VHL gene is crucial in patients with CNS hemangioblastoma.
  • [MeSH-minor] Adolescent. Adult. Cerebellar Neoplasms. Child. Child, Preschool. DNA Mutational Analysis. Female. Genetic Testing. Humans. Male. Mexico. Middle Aged. Pedigree. Prognosis

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16572651.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kosaka N, Tsuchida T, Uematsu H, Kimura H, Okazawa H, Itoh H: 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol; 2008 Jun;190(6):W365-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET of common enhancing malignant brain tumors.
  • OBJECTIVE: The purpose of our study was to determine whether (18)F-FDG PET can be used to differentiate among common enhancing brain tumors such as lymphoma, high-grade glioma, and metastatic brain tumor.
  • MATERIALS AND METHODS: We evaluated 34 patients with an enhancing brain tumor on MRI, including seven lymphomas, nine high-grade gliomas, and 18 metastatic tumors.
  • For PET image analysis, regions of interest were placed over the tumor (T), contralateral cortex (C), and white matter (WM).
  • RESULTS: All parameters were significantly higher for lymphoma than for other tumors (p < 0.01).
  • High-grade gliomas showed significantly higher SUV(avg) and SUV(max) than metastatic tumors (p < 0.05).
  • Using an SUV(max) of 15.0 as a cutoff for diagnosing CNS lymphoma, only one high-grade glioma was found as a false-positive (SUV(max), 18.8).
  • CONCLUSION: FDG PET may be useful for differentiating common enhancing malignant brain tumors, particularly lymphoma versus high-grade glioma and metastatic tumor.
  • FDG PET can provide useful information for distinguishing between lymphoma and other malignant enhancing brain tumors and is recommended when differential diagnoses are difficult to narrow using MRI alone.
  • [MeSH-major] Algorithms. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18492879.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


23. Fanburg-Smith JC, Auerbach A, Marwaha JS, Wang Z, Santi M, Judkins AR, Rushing EJ: Immunoprofile of mesenchymal chondrosarcoma: aberrant desmin and EMA expression, retention of INI1, and negative estrogen receptor in 22 female-predominant central nervous system and musculoskeletal cases. Ann Diagn Pathol; 2010 Feb;14(1):8-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoprofile of mesenchymal chondrosarcoma: aberrant desmin and EMA expression, retention of INI1, and negative estrogen receptor in 22 female-predominant central nervous system and musculoskeletal cases.
  • Mesenchymal chondrosarcoma is a rare malignant tumor in the differential diagnosis of other small, round blue cell tumors, including atypical teratoid tumor in the central nervous system (CNS) and rhabdomyosarcoma in the musculoskeletal (MSK) locations.
  • We reviewed the morphology of CNS and MSK cases and applied a panel of immunostains.
  • Twenty-two cases included 5 CNS (all female; mean age, 30.2) and 17 MSK (11 female and 6 male; mean age, 31.1).
  • Both CNS and MSK examples had similar round cells, staghorn vascular pattern, increased mitotic activity, and centrally located hyaline cartilage islands.
  • The CNS examples demonstrated more spindling and the MSK cases more necrosis.
  • INI1 was retained in all tumors studied.
  • The CNS and MSK mesenchymal chondrosarcoma predominantly affects adult females with poor prognosis.
  • There are only subtle morphologic differences between the CNS and MSK groups.
  • Retained INI1 separates these tumors from atypical teratoid tumor.
  • [MeSH-major] Bone Neoplasms / pathology. Chondrosarcoma, Mesenchymal / pathology. Chromosomal Proteins, Non-Histone / metabolism. DNA-Binding Proteins / metabolism. Desmin / metabolism. Mucin-1 / metabolism. Nervous System Neoplasms / pathology. Receptors, Estrogen / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Child. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20123451.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Desmin; 0 / Mucin-1; 0 / Receptors, Estrogen; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


24. Ferguson SD, Foster K, Yamini B: Convection-enhanced delivery for treatment of brain tumors. Expert Rev Anticancer Ther; 2007 Dec;7(12 Suppl):S79-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Convection-enhanced delivery for treatment of brain tumors.
  • Convection-enhanced delivery is a promising method for the delivery of macromolecules to the CNS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Chemotherapy, Cancer, Regional Perfusion / methods. Glioma / drug therapy. Infusion Pumps, Implantable
  • [MeSH-minor] Adult. Animals. Clinical Trials as Topic. Convection. Disease Models, Animal. Female. Humans. Male. Prognosis. Rats. Risk Assessment. Sensitivity and Specificity. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076322.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 46
  •  go-up   go-down


25. Fuller CE, Perry A: Molecular diagnostics in central nervous system tumors. Adv Anat Pathol; 2005 Jul;12(4):180-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnostics in central nervous system tumors.
  • Central nervous system (CNS) neoplasms can be diagnostically challenging, due to remarkably wide ranges in histologic appearance, biologic behavior, and therapeutic approach.
  • In this regard, the field is primed by recent advances in basic research, elucidating the molecular mechanisms of tumorigenesis and progression in the most common adult and pediatric brain tumors.
  • Thus far, few have made the transition into routine clinical practice, the most notable example being 1p and 19q testing in oligodendroglial tumors.
  • The goal of this article is to highlight the most common genetic alterations currently implicated in CNS tumors, focusing most on those that are either already in common use in ancillary molecular diagnostics testing or are likely to become so in the near future.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Central Nervous System Neoplasms / genetics. Ependymoma / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Chromosome Aberrations. Humans. In Situ Hybridization, Fluorescence. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / genetics. Meningioma / diagnosis. Meningioma / genetics. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / genetics. Polymerase Chain Reaction. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096380.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 260
  •  go-up   go-down


26. Anclair M, Hovén E, Lannering B, Boman KK: Parental fears following their child's brain tumor diagnosis and treatment. J Pediatr Oncol Nurs; 2009 Mar-Apr;26(2):68-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parental fears following their child's brain tumor diagnosis and treatment.
  • The objective of this study is to portray the illness-related threats experienced by parents of children after the diagnosis of central nervous system (CNS) tumor.
  • Parents were asked to rate the extent to which they experienced a set of specific fears related to their child's brain tumor and its treatment.
  • Outcomes for parents of CNS tumor patients (n = 82) were compared with those of reference parents of patients treated for acute lymphoblastic leukemia (n = 208).
  • The fears about an illness recurrence and the late effects of treatment were most prominent among parents of CNS tumor patients.
  • For 7 out of 11 kinds of fear, parents of CNS tumor patients expressed a stronger fear than the reference group.
  • More than a quarter of the parents of children treated for CNS tumors feared a complete decline of the child.
  • Parents of CNS tumor patients experience relatively heightened cancer related fears in several domains.
  • [MeSH-major] Brain Neoplasms / psychology. Fear. Parents / psychology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cross-Sectional Studies. Humans. Infant. Infant, Newborn

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190177.001).
  • [ISSN] 1043-4542
  • [Journal-full-title] Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses
  • [ISO-abbreviation] J Pediatr Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Ronckers CM, McCarron P, Ron E: Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer; 2005 Nov 1;117(2):281-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid cancer and multiple primary tumors in the SEER cancer registries.
  • Based on small numbers of cases, cancers of the salivary glands, trachea, scrotum, adrenal glands, and brain and central nervous system (CNS) also occurred in excess.
  • Although enhanced medical surveillance likely plays a role, 2-way, positive associations between thyroid cancer and cancers of the breast, prostate, kidney, salivary glands, brain and CNS, scrotum, and leukemia suggest etiologic similarities and possible treatment effects.
  • [MeSH-major] Neoplasms, Multiple Primary / epidemiology. Thyroid Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. National Institutes of Health (U.S.). Registries. Risk. United States / epidemiology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880372.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Kim CY, Paek SH, Jeong SS, Chung HT, Han JH, Park CK, Jung HW, Kim DG: Gamma knife radiosurgery for central neurocytoma: primary and secondary treatment. Cancer; 2007 Nov 15;110(10):2276-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife radiosurgery for central neurocytoma: primary and secondary treatment.
  • BACKGROUND: Little is known about long-term results of gamma knife (GK) stereotactic radiosurgery (SRS) as a primary or a secondary postoperative therapy for central neurocytomas (CNs).
  • Tumors decreased in 5 patients who received GK SRS as a primary treatment.
  • However, the tumor recurred in 2 patients treated with a secondary GK SRS after surgery from the residual tumor bed that was not covered by the GK SRS.
  • [MeSH-major] Brain Neoplasms / surgery. Neurocytoma / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17926332.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Powers JF, Evinger MJ, Zhi J, Picard KL, Tischler AS: Pheochromocytomas in Nf1 knockout mice express a neural progenitor gene expression profile. Neuroscience; 2007 Jul 29;147(4):928-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytomas are adrenal medullary tumors that typically occur in adult patients, with increased frequency in multiple endocrine neoplasia type 2, von Hippel-Lindau disease, familial paraganglioma syndromes and neurofibromatosis type 1 (NF1).
  • Pheochromocytomas arise in adult mice with a heterozygous knockout mutation of exon 31 of the murine Nf1 gene, providing a mouse model for pheochromocytoma development in NF1.
  • We performed a microarray-based gene expression profiling study comparing mouse pheochromocytoma tissue to normal adult mouse adrenal medulla to develop a basis for studying the pathobiology of these tumors.
  • The findings demonstrate that pheochromocytomas from adult neurofibromatosis knockout mice express multiple developmentally regulated genes involved in early development of both the CNS and peripheral nervous system.
  • One of the most highly overexpressed genes is receptor tyrosine kinase Ret, which is known to be transiently expressed in the developing adrenal gland, down-regulated in adult adrenals and often overexpressed in human pheochromocytomas.
  • The findings are consistent with the recently proposed concept that persistent neural progenitors might give rise to pheochromocytomas in adult mouse adrenals and suggest that events predisposing to tumor development might occur before formation of the adrenal medulla or migration of cells from the neural crest.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Neurofibromin 1 / deficiency. Pheochromocytoma / genetics. Proto-Oncogene Proteins c-ret / metabolism

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582688.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM 46588; United States / NINDS NIH HHS / NS / NS 36785
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 1; 0 / RNA, Messenger; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / Ret protein, mouse
  •  go-up   go-down


30. Yağmurlu B, Akyürek S, Fitoz S, Demirkazik A: MRI of non-neoplastic cranial complications of malignant disorders. Diagn Interv Radiol; 2008 Jun;14(2):61-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To depict the well-known and atypical magnetic resonance imaging (MRI) findings of non-neoplastic central nervous system (CNS) complications of extra- CNS tumors and portray additional information from advanced techniques, such as diffusion and perfusion MRI.
  • MATERIALS AND METHODS: MRI scans of 92 patients were retrospectively evaluated based on the non-neoplastic effects induced by treatment or the remote effects of the tumor itself.
  • Three patients had bilateral radionecrosis of the temporal lobe due to radiotherapy given for the vicinal tumor (nasopharyngeal carcinoma).
  • [MeSH-major] Brain / pathology. Central Nervous System Diseases / diagnosis. Central Nervous System Diseases / etiology. Magnetic Resonance Imaging / methods. Neoplasms / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Central Nervous System Neoplasms / complications. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / secondary. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18553277.001).
  • [ISSN] 1305-3612
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


31. Rodriguez FJ, Scheithauer BW, Robbins PD, Burger PC, Hessler RB, Perry A, Abell-Aleff PC, Mierau GW: Ependymomas with neuronal differentiation: a morphologic and immunohistochemical spectrum. Acta Neuropathol; 2007 Mar;113(3):313-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The category of mixed glioneuronal tumors of the CNS is rapidly losing its definition as encompassing tumors composed of histologically distinct neuron variants and glia.
  • The tumors affected a 16-year-old male and a 5-year-old female and involved the right frontoparietal lobe and fourth ventricle, respectively.
  • Five tumors each were WHO grade II and III.
  • [MeSH-major] Cell Differentiation. Central Nervous System Neoplasms / metabolism. Central Nervous System Neoplasms / pathology. Ependymoma / pathology. Neurons / physiology
  • [MeSH-minor] Adult. Child, Preschool. Female. Humans. Infant. Male. Microscopy, Electron, Transmission. Nerve Tissue Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061076.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins
  •  go-up   go-down


32. Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L: EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol; 2009 Apr;20(4):648-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In an attempt to identify markers of resistance to trastuzumab, we evaluated both the profiling of human epidermal growth factor receptor 2 (HER2)-positive tumor cells measuring the relative levels of EGFR, pMAPK, pAkt and PTEN and their correlations with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
  • PATIENTS AND METHODS: Tumor tissues for this retrospective analysis were available from 45 out of 76 patients with metastatic breast cancer treated from April 1999 to March 2006 with trastuzumab-based therapy at our Institution.
  • Evaluations of EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry (IHC) were carried out on all 45 tissue samples and their correlations with response to trastuzumab, incidence of central nervous system (CNS) metastases, time to progression (TTP), overall survival from diagnosis of breast cancer (OS1), from diagnosis of metastatic disease (OS2) and from the start of trastuzumab (OS3) were analyzed.
  • EGFR, pMAPK, pAkt and PTEN status by IHC were not significantly associated with response to trastuzumab, TTP, overall survival (OS1, OS2, OS3) and CNS metastases incidence.
  • It is likely that high expression of pMAPK (pMAPK-positive status) or pAkt (pAkt-positive status) could identify a subgroup of HER2-positive tumors with high activity of proliferation and survival pathways and with resistance to trastuzumab.
  • CONCLUSIONS: In HER2-positive metastatic breast cancers, EGFR, pMAPK, pAkt and PTEN status evaluated by IHC was not significantly associated with response to trastuzumab, TTP, OS and CNS metastases incidence.


33. Park DM, Zhuang Z, Chen L, Szerlip N, Maric I, Li J, Sohn T, Kim SH, Lubensky IA, Vortmeyer AO, Rodgers GP, Oldfield EH, Lonser RR: von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med; 2007 Feb;4(2):e60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To determine the origin of the neoplastic cell in central nervous system (CNS) hemangioblastomas in von Hippel-Lindau disease (VHL) and its role in tumor formation and distribution, we characterized and differentiated neoplastic cells from hemangioblastomas removed from VHL patients.
  • METHODS AND FINDINGS: A total of 31 CNS hemangioblastomas from 25 VHL patients were resected and analyzed.
  • Tumor cells from the hemangioblastomas were characterized, grown, and differentiated into multiple lineages.
  • Resected hemangioblastomas were located in the cerebellum (11 tumors), brainstem (five tumors), and spinal cord (15 tumors).
  • CONCLUSIONS: The neoplastic cell of origin for CNS hemangioblastomas in VHL patients is the mesoderm-derived, embryologically arrested hemangioblast.
  • These findings may also explain the unique tissue distribution of tumor involvement.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Hemangioblastoma / pathology. Multipotent Stem Cells / pathology. von Hippel-Lindau Disease / complications
  • [MeSH-minor] Adolescent. Adult. Antigens, CD13 / genetics. Blotting, Western. Cell Degranulation. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. RNA, Neoplasm / genetics. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured


34. Barrera M, Shaw AK, Speechley KN, Maunsell E, Pogany L: Educational and social late effects of childhood cancer and related clinical, personal, and familial characteristics. Cancer; 2005 Oct 15;104(8):1751-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survivors of central nervous system (CNS) tumors reportedly were more likely than controls to have educational problems and no close friends, followed by survivors of leukemia, and survivors of neuroblastoma.
  • CONCLUSIONS: Children and adolescents who survived cancer, particularly those who had CNS tumors, leukemia, and neuroblastoma, required close monitoring for early educational and social difficulties, and such children should be offered educational rehabilitation and social skills training to maximize their academic and social success.
  • [MeSH-major] Educational Status. Neoplasms / psychology. Social Behavior
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Employment. Female. Follow-Up Studies. Humans. Male. Parents. Retrospective Studies. Survivors


35. Honig A, Rieger L, Sutterlin A, Kapp M, Dietl J, Sutterlin MW, Kämmerer U: Brain metastases in breast cancer--an in vitro study to evaluate new systemic chemotherapeutic options. Anticancer Res; 2005 May-Jun;25(3A):1531-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Fifteen-30% of breast cancer patients develop central nervous system (CNS) metastases.
  • Drugs with proven efficacy in the CNS and which are commonly used for primary brain tumors were applied.
  • We evaluated the capacity of these drugs to inhibit breast tumor cell growth in vitro.
  • The data and the "liposomal packaging" suggest that Caelyx might be effective in the CNS.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / secondary. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Humans. In Vitro Techniques. Middle Aged. Tumor Cells, Cultured


36. Selkirk SM, Morrow J, Barone TA, Hoffer A, Lock J, DeChant A, Mangla S, Plunkett RJ, Miller RH: Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal. J Neurooncol; 2008 Feb;86(3):285-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal.
  • Osteopontin (OPN) is a pleotrophic molecule that has been associated with multiple disorders of the central nervous system (CNS).
  • Its roles in CNS malignancy are unclear but suggest that higher levels of OPN expression correlate with increased tumor grade and increased migratory capacity of tumor cells.
  • Implantation of tumor cells expressing high levels of OPN into adult Fischer rats and nude rats resulted in morphologically distinct tumors and prolonged host survival relative to controls.
  • We propose that local produced, high level OPN expression limits the malignant character of glioma cells and that the downstream mechanisms involved represent pathways that may have therapeutic value in the treatment of human CNS malignancy.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36328-34 [10593924.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10024-31 [17047065.001]
  • [Cites] Exp Cell Res. 2000 Aug 1;258(2):342-51 [10896785.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24565-74 [10835423.001]
  • [Cites] Int J Exp Pathol. 2000 Dec;81(6):373-90 [11298186.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28261-7 [11375993.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1731-5 [11721059.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46024-30 [11590166.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] QJM. 2002 Jan;95(1):3-13 [11834767.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5336-43 [12235004.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6318-22 [12414663.001]
  • [Cites] Oncogene. 2003 Feb 27;22(8):1198-205 [12606946.001]
  • [Cites] J Neuroimmunol. 2003 Mar;136(1-2):125-9 [12620651.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28593-606 [12771144.001]
  • [Cites] Mol Cancer Res. 2003 Sep;1(11):810-9 [14517343.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11051-64 [14704150.001]
  • [Cites] J Neuroimmunol. 2004 Oct;155(1-2):155-60 [15342207.001]
  • [Cites] Cell. 1979 Apr;16(4):885-93 [88265.001]
  • [Cites] J Biol Chem. 1987 Feb 25;262(6):2900-7 [3469201.001]
  • [Cites] J Biol Chem. 1987 Jul 15;262(20):9702-8 [3597437.001]
  • [Cites] J Exp Med. 1989 Jul 1;170(1):145-61 [2787378.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):426-30 [1729712.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):610-23 [8080043.001]
  • [Cites] Biochem J. 1994 Oct 1;303 ( Pt 1):255-62 [7945249.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]
  • [Cites] J Clin Invest. 1995 Feb;95(2):713-24 [7532190.001]
  • [Cites] Lung Cancer. 1996 Nov;15(3):311-23 [8959677.001]
  • [Cites] J Biol Chem. 1997 Apr 11;272(15):10110-6 [9092556.001]
  • [Cites] Arch Pathol Lab Med. 1997 Jun;121(6):578-84 [9199622.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):219-26 [9892210.001]
  • [Cites] J Cell Biochem Suppl. 1998;30-31:92-102 [9893260.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):19381-92 [15757900.001]
  • [Cites] Trends Cell Biol. 2006 Feb;16(2):79-87 [16406521.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6638-48 [16818637.001]
  • [Cites] Bioessays. 2006 Sep;28(9):923-34 [16937364.001]
  • [Cites] Ann N Y Acad Sci. 1999;890:204-22 [10668427.001]
  • (PMID = 17928956.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA10373602; United States / NINDS NIH HHS / NS / R01 NS036674; United States / NINDS NIH HHS / NS / NS030800-14; United States / NINDS NIH HHS / NS / R01 NS030800; United States / NINDS NIH HHS / NS / NS-3080011; United States / NINDS NIH HHS / NS / R37 NS036674; United States / NINDS NIH HHS / NS / R01 NS030800-14; United States / NINDS NIH HHS / NS / NS-36674-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 106441-73-0 / Osteopontin; 147336-22-9 / Green Fluorescent Proteins; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ NIHMS196650; NLM/ PMC2911624
  •  go-up   go-down


37. Leyhe T, Morawetz C, Zank M, Buchkremer G, Eschweiler GW: Epilepsy in an elderly patient caused by Hashimoto's encephalopathy. Epileptic Disord; 2007 Sep;9(3):337-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Late-onset seizures are frequently caused by cerebrovascular disease, head trauma, degenerative disorders or CNS tumors.
  • In only 60-70% of adult-onset epilepsy is antiepileptic drug treatment successful.

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884760.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Anticonvulsants; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


38. Villano JL, Virk IY, Ramirez V, Propp JM, Engelhard HH, McCarthy BJ: Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis. Neuro Oncol; 2010 Mar;12(3):257-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis.
  • Central nervous system (CNS) germ cell tumors (GCT) have not been epidemiologically well described.
  • Our study describes 2 population-based series of nonpineal CNS GCT.
  • Data on all primary (malignant and nonmalignant) CNS (ICD-O-3 sites: C70.0-C72.9, C75.1-C75.3) GCT diagnosed between 2000 and 2004 from the Central Brain Tumor Registry of the United States (CBTRUS) and on all malignant GCT diagnosed between 1992 and 2005 from the Surveillance, Epidemiology, and End Results (SEER) were analyzed.
  • For children and young adults, most tumors were malignant (86.8% and 89.0%, respectively), whereas for adults, more than half were nonmalignant (56.8%).
  • In SEER, the frequency of malignant GCT in the CNS (2.5%) was greater than that in the mediastinum (2.1%).
  • Of 408 malignant CNS GCT, 216 (52.9%) were nonpineal.
  • Overall relative survival for nonpineal CNS malignant GCT was 85.3% at 2 years, 77.3% at 5 years, and 67.6% at 10 years.
  • Nonpineal CNS GCT show no significant gender preference, yet have outcomes similar to pineal GCT.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Neoplasms, Germ Cell and Embryonal / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Registries. SEER Program. United States / epidemiology. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2585-92 [10561326.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):121-30 [18287340.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1171-6 [10725628.001]
  • [Cites] Oncologist. 2000;5(4):312-20 [10964999.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):815-21 [11005262.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7268-76 [11585765.001]
  • [Cites] Int J Clin Oncol. 2001 Aug;6(4):183-91 [11706556.001]
  • [Cites] Brain Tumor Pathol. 2001;18(2):115-22 [11908867.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):487-500 [12354131.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):846-53 [14990640.001]
  • [Cites] Pediatr Blood Cancer. 2004 Aug;43(2):126-33 [15236278.001]
  • [Cites] Am J Clin Pathol. 1976 Apr;65(4):450-4 [178171.001]
  • [Cites] J Neurosurg. 1985 Aug;63(2):155-67 [2991485.001]
  • [Cites] Int J Androl. 1987 Feb;10(1):43-9 [3034798.001]
  • [Cites] J Neurosurg. 1987 Jul;67(1):65-70 [2439668.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Sep-Oct;10(5):1039-44 [2476011.001]
  • [Cites] Pediatr Pathol. 1990;10(1-2):231-41 [2156245.001]
  • [Cites] Chest. 1991 Feb;99(2):472-9 [1846573.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):545-51 [1848284.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Dec;5(6):1189-209 [1663939.001]
  • [Cites] Radiat Med. 1992 Mar-Apr;10(2):55-61 [1320768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):229-45 [8270446.001]
  • [Cites] Neuropediatrics. 1994 Feb;25(1):26-32 [8208347.001]
  • [Cites] Med Pediatr Oncol. 1995 Jun;24(6):368-72 [7536294.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] J Neurooncol. 1997 Mar;32(1):71-80 [9049865.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):681-90 [9264351.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1792-7 [9351549.001]
  • [Cites] Childs Nerv Syst. 1999 Mar;15(2-3):119-26; discussion 127 [10230668.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):133-7 [10413166.001]
  • [Cites] Bull N Y Acad Med. 1950 Jul;26(7):440-60 [15426876.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] J Neurosurg. 2005 Dec;103(6 Suppl):524-30 [16383251.001]
  • [Cites] Obstet Gynecol. 2006 May;107(5):1075-85 [16648414.001]
  • [Cites] Urology. 2006 Aug;68(2):402-5; discussion 405 [16904461.001]
  • [Cites] Neurology. 2007 May 15;68(20):1668-73 [17502547.001]
  • [Cites] Childs Nerv Syst. 2008 Jan;24(1):71-8 [17906866.001]
  • [Cites] J Neurooncol. 1999 Aug;44(1):71-6 [10582672.001]
  • (PMID = 20167813.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940596
  •  go-up   go-down


39. Rodríguez D, Cheung MC, Housri N, Quinones-Hinojosa A, Camphausen K, Koniaris LG: Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005). J Surg Res; 2009 Oct;156(2):340-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005).
  • BACKGROUND: Determine the role of surgery and radiation therapy for patients with malignant CNS ependymomas.
  • Univariate analysis demonstrated that age, gender, ethnicity, primary tumor site, WHO grade and surgical resection were significant predictors of improved survival for ependymoma patients.
  • Multivariate analysis identified that a WHO grade III tumor, male gender, patient age, intracranial tumor locations and failure to undergo surgical resection were independent predictors of poorer outcomes.
  • For partially resected tumors, radiation therapy provides significant survival benefit.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Central Nervous System Neoplasms / surgery. Ependymoma / radiotherapy. Ependymoma / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. SEER Program. Treatment Outcome. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577759.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Shono T, Tosaka M, Matsumoto K, Onaka S, Yamaguchi S, Mizoguchi M, Iwaki T, Nakazato Y, Sasaki T: Ganglioglioma in the third ventricle: report on two cases. Neurosurg Rev; 2007 Jul;30(3):253-8; discussion 258
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gangliogliomas are uncommon central nervous system (CNS) tumors composed of a mixture of glial and neuronal elements.
  • Although these tumors can occur in any portion of the central nervous system, involvement of the ventricular system is rare.
  • In the first case the tumor in the middle portion of the third ventricle was successfully removed by a transcallosal subchoroidal approach.
  • In the second case the hemorrhagic tumor was located in the anterior floor of the third ventricle and was removed by an anterior inter-hemispheric trans-lamina terminalis approach.
  • To date, follow-ups of both patients have involved no adjuvant therapy, and there have been no signs of tumor recurrence on magnetic resonance images.
  • The nature, radiological findings, and treatments of these tumors are discussed.
  • [MeSH-major] Cerebral Ventricle Neoplasms / surgery. Ganglioglioma / surgery. Third Ventricle / surgery
  • [MeSH-minor] Adult. Astrocytes / pathology. Biopsy. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgical Procedures. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ganglioglioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1998 Jun;42(6):1205-17; discussion 1217-9 [9632178.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Neurosurgery. 1992 Aug;31(2):171-8 [1513423.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):428-33 [3574619.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):3-11 [2352020.001]
  • [Cites] Neurosurgery. 1997 May;40(5):973-81; discussion 981-2 [9149256.001]
  • [Cites] J Neurosurg. 1986 Aug;65(2):177-82 [3723174.001]
  • [Cites] J Neurooncol. 1993 Aug;17(2):139-54 [8145057.001]
  • [Cites] Surg Neurol. 1988 Jul;30(1):3-59 [3394010.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Dec;57(12):1497-502 [7798980.001]
  • [Cites] Neurosurgery. 1982 May;10(5):547-54 [7099406.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Sep;43 Suppl:i-vii, 1-111 [14705327.001]
  • [Cites] J Neurosurg. 1984 Feb;60(2):431-4 [6693970.001]
  • [Cites] Neurosurgery. 1983 Jan;12 (1):86-94 [6828226.001]
  • [Cites] Surg Neurol. 1984 Apr;21(4):325-31 [6701763.001]
  • [Cites] J Neurosurg. 1993 Dec;79(6):859-66 [8246054.001]
  • [Cites] Surg Neurol. 1991 Apr;35(4):261-6 [2008640.001]
  • [Cites] Neurosurg Rev. 2001 Mar;24(1):14-9 [11339462.001]
  • [Cites] Surg Neurol. 1984 Aug;22(2):157-63 [6740479.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):127-31 [8988736.001]
  • [Cites] J Neurosurg. 1991 Jul;75(1):134-7 [2045898.001]
  • [Cites] J Neurosurg. 1993 Dec;79(6):867-73 [8246055.001]
  • [Cites] Acta Neurochir (Wien). 1993;125(1-4):52-7 [8122557.001]
  • [Cites] Neuroradiology. 1998 Jun;40(6):377-9 [9689626.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Jan-Feb;11(1):109-14 [2105590.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(2):135-41 [10189494.001]
  • (PMID = 17492319.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Bhattacharyya I, Chehal HK, Cohen DM, Al-Quran SZ: Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification. Head Neck Pathol; 2010 Sep;4(3):181-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies validating this classification have been done for DLBCL of the breast, CNS, testes and GI tract.
  • All tumors showed frequent labeling with Ki-67 (range 40-95%).
  • [MeSH-major] Germinal Center / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Disease-Free Survival. Fatal Outcome. Female. Humans. Immunohistochemistry. Interferon Regulatory Factors / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neprilysin / metabolism. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1998 Aug;25(4):483-91 [9728598.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):117-22 [9894462.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):423-9 [10458261.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):545-51 [15517363.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):398-405 [15492762.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):303-10 [15716836.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):247-57 [16342164.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1521-7 [16998463.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):447-54 [18086797.001]
  • [Cites] Hematology. 2009 Apr;14(2):84-9 [19298719.001]
  • [Cites] Cancer Sci. 2009 Oct;100(10):1842-7 [19656156.001]
  • [Cites] Mod Pathol. 2010 Feb;23(2):235-43 [19935644.001]
  • [Cites] Blood. 2000 Jan 15;95(2):651-9 [10627476.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1797-803 [10688840.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):846-52 [10843287.001]
  • [Cites] Immunity. 2000 Aug;13(2):199-212 [10981963.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1244-52 [11106083.001]
  • [Cites] Mod Pathol. 2001 Feb;14(2):105-10 [11235901.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):325-34 [11555708.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):1089-98 [11697626.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):153-7 [11957138.001]
  • [Cites] Br J Haematol. 2002 May;117(2):322-32 [11972514.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] J Pathol. 1988 Mar;154(3):223-35 [2450981.001]
  • [Cites] J Clin Pathol. 1989 Nov;42(11):1194-200 [2531171.001]
  • [Cites] Am J Pathol. 1990 Aug;137(2):225-32 [2201196.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1190-7 [2205355.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):231-6 [8508412.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Science. 1993 Oct 29;262(5134):747-50 [8235596.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Mod Pathol. 2002 Aug;15(8):807-16 [12181265.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1366-73 [12481019.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):722-8 [12576441.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1063-9 [12631608.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1269-77 [12960812.001]
  • [Cites] Histopathology. 2003 Dec;43(6):509-28 [14636252.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3498-506 [15337798.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5948-55 [15342373.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):407-12 [3819806.001]
  • [Cites] Ann Intern Med. 1987 Jul;107(1):25-30 [3296898.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994;30B(2):121-5 [8032301.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Pathol. 1996 May;148(5):1543-55 [8623923.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Aug;82(2):173-8 [8863307.001]
  • (PMID = 20533006.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC2923304
  •  go-up   go-down


42. Rajaram V, Gutmann DH, Prasad SK, Mansur DB, Perry A: Alterations of protein 4.1 family members in ependymomas: a study of 84 cases. Mod Pathol; 2005 Jul;18(7):991-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymomas are common pediatric and adult CNS malignancies with a wide biologic spectrum that is often hard to predict using classic prognostic variables.
  • The majority of cases harbored one or more detectable genetic alterations, but we found that 4.1B gene deletions and 4.1R loss of expression were statistically more common in the pediatric vs adult, intracranial vs spinal, and grade III vs grade I/II subsets (P-values of 0.038 to <0.001).
  • Also, 4.1G deletions were seen in 11/27 (41%) patients who either died of disease or had residual/recurrent tumor vs 5/41 patients with no evidence of disease at last follow-up (P=0.009).
  • We conclude that alterations of Protein 4.1 family members are common in ependymal tumors and that specific alterations are associated with distinct clinicopathologic subsets.
  • [MeSH-minor] Adolescent. Adult. Aged. Blood Proteins / analysis. Blood Proteins / genetics. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Child. Child, Preschool. Cohort Studies. Cytoskeletal Proteins / analysis. Cytoskeletal Proteins / genetics. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Microfilament Proteins. Microtubule-Associated Proteins / analysis. Microtubule-Associated Proteins / genetics. Middle Aged. Neurofibromin 2 / analysis. Neurofibromin 2 / genetics. Spinal Cord Neoplasms / genetics. Spinal Cord Neoplasms / metabolism. Spinal Cord Neoplasms / pathology. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15731777.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Cytoskeletal Proteins; 0 / EPB41L3 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Microtubule-Associated Proteins; 0 / Neurofibromin 2; 0 / Tumor Suppressor Proteins; 0 / erythrocyte membrane band 4.1 protein
  •  go-up   go-down


43. Grodman H, Wolfe L, Kretschmar C: Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue. Pediatr Blood Cancer; 2009 Jul;53(1):33-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue.
  • BACKGROUND: Adults and children with recurrent malignant central nervous system (CNS) tumors have a poor prognosis despite high dose chemotherapy with a conventional stem cell rescue regimen.
  • In this study we evaluated the results of low dose, continuous infusion etoposide over 21 days added to a conventional high-dose regimen of carboplatin and thiotepa in eight patients with relapsed pediatric CNS tumors.
  • PROCEDURE: Patients with high risk CNS tumors were treated with etoposide 25 mg/m(2)/day by continuous intravenous (IV) infusion from day -22 to day -2, carboplatin 667 mg/m(2)/dose IV (or area under the curve = 9 mg/ml/min according to the Calvert formula on days -8, -7, and -6, and thiotepa 300 mg/m(2)/dose IV on days -5, -4, and -3, followed by autologous hematopoietic stem cell rescue on day 0.
  • RESULTS: Eight adults and children, with a mean age of 12.9 years (age range 5.6-27.8 years), with relapsed primary CNS tumors (metastatic medulloblastoma (7), germinoma (1)), were enrolled.
  • This treatment strategy deserves further evaluation in a larger group of high-risk or relapsed primary CNS tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / therapy. Etoposide / administration & dosage. Germinoma / therapy. Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adolescent. Adult. Anemia / chemically induced. Anemia / therapy. Carboplatin / administration & dosage. Child. Child, Preschool. Female. Hematologic Diseases / chemically induced. Hematologic Diseases / therapy. Humans. Infusions, Intravenous. Male. Survival Rate. Thiotepa / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Germinoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19326417.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin
  •  go-up   go-down


44. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD: IDH1 and IDH2 mutations in gliomas. N Engl J Med; 2009 Feb 19;360(8):765-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A recent genomewide mutational analysis of glioblastomas (World Health Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in a fraction of such tumors, most frequently in tumors that were known to have evolved from lower-grade gliomas (secondary glioblastomas).
  • METHODS: We determined the sequence of the IDH1 gene and the related IDH2 gene in 445 central nervous system (CNS) tumors and 494 non-CNS tumors.
  • Tumors without mutations in IDH1 often had mutations affecting the analogous amino acid (R172) of the IDH2 gene.
  • Tumors with IDH1 or IDH2 mutations had distinctive genetic and clinical characteristics, and patients with such tumors had a better outcome than those with wild-type IDH genes.

  • Genetics Home Reference. consumer health - IDH1 gene.
  • Genetics Home Reference. consumer health - IDH2 gene.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827855335 for PMID:19228619 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Massachusetts Medical Society
  • [Cites] Cancer Res. 1996 Jan 1;56(1):150-3 [8548755.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):983-94 [8806688.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9 [1557402.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):375-86 [10433931.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2683-710 [17974913.001]
  • [Cites] Free Radic Res. 2008 Jul;42(7):618-24 [18608518.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3089-94 [14970324.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [CommentIn] N Engl J Med. 2009 May 21;360(21):2248; author reply 2249 [19458374.001]
  • [CommentIn] N Engl J Med. 2009 May 21;360(21):2248-9; author reply 2249 [19469031.001]
  • [CommentIn] N Engl J Med. 2009 Feb 19;360(8):813-5 [19228626.001]
  • (PMID = 19228619.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA043460-27; United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R01CA118822; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R37 CA043460-27; United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / 2P30-CA-14236; United States / NCI NIH HHS / CA / 5P50-CA-108786; United States / NCI NIH HHS / CA / CA121113; United States / NCI NIH HHS / CA / CA062924-150012; United States / NCI NIH HHS / CA / R37 CA043460-26; United States / NCI NIH HHS / CA / 5R37-CA-11898; United States / NCI NIH HHS / CA / R37CA11898-34; United States / NCI NIH HHS / CA / R01 CA121113; United States / NCI NIH HHS / CA / R01 CA140316; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA043460-26; United States / NCI NIH HHS / CA / R01 CA121113-04; United States / NINDS NIH HHS / NS / NS20023-21; United States / NCI NIH HHS / CA / CA057345-17; United States / NCI NIH HHS / CA / R37 CA057345-17; United States / NCI NIH HHS / CA / R37 CA057345; United States / NCI NIH HHS / CA / P30 CA014236; United States / NCI NIH HHS / CA / P50 CA062924-150012; United States / NCI NIH HHS / CA / R01 CA057345; United States / NCI NIH HHS / CA / R01 CA118822; United States / NINDS NIH HHS / NS / 5P50-NS-20023; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.41 / isocitrate dehydrogenase 2, human
  • [Other-IDs] NLM/ NIHMS107443; NLM/ PMC2820383
  •  go-up   go-down


45. Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F, Melchiorri D: Metabotropic glutamate receptors: new targets for the control of tumor growth? Trends Pharmacol Sci; 2007 May;28(5):206-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabotropic glutamate receptors: new targets for the control of tumor growth?
  • Cancer stem cells are currently a target for the treatment of malignant tumors.
  • Transformed neural stem-progenitor cells of the brain subventricular zone and the external granular layer of the cerebellum are the putative cells of origin of malignant gliomas and medulloblastomas, which are the most frequent malignant brain tumors in adults and children, respectively.
  • The proliferation of neural stem-progenitor cells is regulated by metabotropic glutamate (mGlu) receptors, which are G-protein-coupled receptors that are activated by glutamate, the major excitatory neurotransmitter of the CNS.
  • At least two receptor subtypes - mGlu(3) and mGlu(4) receptors - control the proliferation of brain tumor cells, whereas mGlu(1) receptors have been implicated in the development of melanomas.
  • We believe that individual mGlu receptor subtypes represent new potential targets for the treatment of several malignant tumors, including brain tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Brain Neoplasms / drug therapy. Drug Delivery Systems. Receptors, Metabotropic Glutamate / drug effects
  • [MeSH-minor] Adult. Animals. Cell Proliferation. Child. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / physiopathology. Drug Resistance, Neoplasm. Gene Expression. Humans. Ligands. Melanoma / drug therapy. Melanoma / physiopathology. Neoplastic Stem Cells / drug effects. Skin Neoplasms / drug therapy. Skin Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433452.001).
  • [ISSN] 0165-6147
  • [Journal-full-title] Trends in pharmacological sciences
  • [ISO-abbreviation] Trends Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ligands; 0 / Receptors, Metabotropic Glutamate
  •  go-up   go-down


46. Lee SS, Kim MK, Sym SJ, Kim SW, Kim WK, Kim SB, Ahn JH: Intramedullary spinal cord metastases: a single-institution experience. J Neurooncol; 2007 Aug;84(1):85-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intramedullary spinal cord metastasis (ISCM) is the rarest type of CNS involvement of systemic malignant tumors.
  • METHODS: We reviewed the medical records of all patients diagnosed with secondary malignant neoplasms involving the spinal cord at the Asan Medical Center between January 1995 and August 2006.
  • Patients were diagnosed with ISCM if they had pathologically established malignancies originating outside the central nervous system (CNS), neurologic symptoms suggestive of spinal cord dysfunction, and either abnormal spinal MRI findings suggestive of ISCM or surgical or postmortem confirmation of ISCM.
  • CONCLUSION: Our findings indicate that ISCM is a very rare type of CNS involvement and represents a dismal finding of systemic malignancy.
  • [MeSH-major] Breast Neoplasms / pathology. Lung Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Cervical Vertebrae. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Thoracic Vertebrae. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol. 1979 Jan 30;220(1):31-41 [84065.001]
  • [Cites] Cancer. 1985 Nov 1;56(9):2305-14 [4052974.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):67-72 [15719278.001]
  • [Cites] Acta Neuropathol. 1983;61(3-4):214-8 [6650133.001]
  • [Cites] Q J Med. 1986 Nov;61(235):1003-20 [3659245.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):43-56 [16215815.001]
  • [Cites] J Neurosurg. 1985 Feb;62(2):227-33 [3968561.001]
  • [Cites] Surg Neurol. 1996 Oct;46(4):329-37; discussion 337-8 [8876713.001]
  • [Cites] Neurology. 1996 Oct;47(4):906-12 [8857717.001]
  • [Cites] J Clin Oncol. 1983 Feb;1(2):99-106 [6321679.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1997;9(5):343-5 [9368732.001]
  • [Cites] Neurosurg Rev. 2001 Jul;24(2-3):88-92 [11485245.001]
  • [Cites] AJR Am J Roentgenol. 1988 Dec;151(6):1193-204 [3263773.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1173-7 [11583203.001]
  • [Cites] J Neurooncol. 2005 Jun;73(2):163-8 [15981107.001]
  • [Cites] Br Med J. 1965 May 22;1(5446):1341-4 [14280299.001]
  • [Cites] AJR Am J Roentgenol. 1987 May;148(5):1015-22 [3554916.001]
  • [Cites] Arch Neurol. 1987 May;44(5):526-31 [3579664.001]
  • [Cites] Surg Neurol. 1988 Sep;30(3):220-7 [3413668.001]
  • [Cites] Neurology. 1972 Dec;22(12 ):1222-31 [4346871.001]
  • (PMID = 17310265.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Cetina L, Candelaria M, Cantu D, Gonzalez-Fierro A, Garcia-Lopez P, Zambrano P, Perez-Plasencia C, Cabrera G, Trejo-Becerril C, Angeles E, Duenas-Gonzalez A: Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer; 2005;4(1):22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.
  • It was recently reported that valproic acid is an effective inhibitor of histone deacetylases and as such induces tumor cell differentiation, apoptosis, or growth arrest.
  • METHODS: Twelve newly diagnosed patients with cervical cancer were treated with magnesium valproate after a baseline tumor biopsy and blood sampling at the following dose levels (four patients each): 20 mg/kg; 30 mg/kg, or 40 mg/kg for 5 days via oral route.
  • At day 6, tumor and blood sampling were repeated and the study protocol ended.
  • Tumor acetylation of H3 and H4 histones and HDAC activity were evaluated by Western blot and colorimetric HDAC assay respectively.
  • After treatment, we observed hyperacetylation of H3 and H4 in the tumors of nine and seven patients, respectively, whereas six patients demonstrated hyperacetylation of both histones.
  • Tumor deacetylase activity decreased in eight patients (80%), whereas two had either no change or a mild increase.
  • There was no correlation between H3 and H4 tumor hyperacetylation with serum levels of valproic acid.
  • CONCLUSION: Magnesium valproate at a dose between 20 and 40 mg/kg inhibits deacetylase activity and hyperacetylates histones in tumor tissues.
  • [MeSH-major] Histone Deacetylases / metabolism. Histones / metabolism. Leukocytes / metabolism. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / metabolism. Valproic Acid / blood. Valproic Acid / therapeutic use
  • [MeSH-minor] Acetylation. Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Middle Aged. Neoplasm Staging


48. Lynam LM, Lyons MK, Drazkowski JF, Sirven JI, Noe KH, Zimmerman RS, Wilkens JA: Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg; 2007 Sep;109(7):634-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review.
  • Brain tumors may lead to symptomatic epilepsy.
  • A retrospective analysis was undertaken to evaluate the frequency of seizure as the presenting symptom leading to brain tumor diagnosis in adults.
  • One hundred and forty-seven consecutive patients with newly diagnosed brain tumors were analyzed regarding the frequency of seizures as the initial presenting symptoms and those subsequently developing seizures.
  • One hundred twelve patients had primary central nervous system tumors (CNS) and 35 had metastatic lesions.
  • Astrocytomas and meningiomas were the most common primary CNS tumors in this study.
  • Seizures were a frequent presenting symptom, occurring in over 38% of those with primary brain neoplasms and 20% of those with cerebral metastases.
  • Primary location of tumor also correlated amongst primary CNS tumors and was associated with a trend in seizure risk: parietal (80%); temporal (74%); frontal (62%); and occipital (0%) (p<0.5).
  • [MeSH-major] Brain Neoplasms / complications. Epilepsy / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cross-Sectional Studies. Epilepsies, Partial / epidemiology. Epilepsies, Partial / etiology. Female. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601658.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


49. Glassmann A, Molly S, Surchev L, Nazwar TA, Holst M, Hartmann W, Baader SL, Oberdick J, Pietsch T, Schilling K: Developmental expression and differentiation-related neuron-specific splicing of metastasis suppressor 1 (Mtss1) in normal and transformed cerebellar cells. BMC Dev Biol; 2007;7:111
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Mtss1 encodes an actin-binding protein, dysregulated in a variety of tumors, that interacts with sonic hedgehog/Gli signaling in epidermal cells.
  • In the adult CNS, Mtss1 is found exclusively in cerebellar Purkinje cells.
  • Whereas immature granule cells express a Mtss1 variant observed also in peripheral tissues and comprising exon 12, this exon is replaced by a CNS-specific exon, 12a, in more mature granule cells and in adult Purkinje cells.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Cerebellum / growth & development. Gene Expression Regulation, Developmental. Microfilament Proteins / genetics. Neoplasm Proteins / genetics
  • [MeSH-minor] Animals. Cerebellar Neoplasms / pathology. Exons. Humans. Mice. Mice, Inbred C57BL. Mice, Transgenic. Polymerase Chain Reaction. Protein Splicing / genetics. Purkinje Cells / pathology. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1996 Feb 29;379(6568):837-40 [8587609.001]
  • [Cites] Neuron. 1996 Mar;16(3):587-99 [8785056.001]
  • [Cites] Biotechniques. 1997 May;22(5):812-4 [9149852.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2085-8 [9187099.001]
  • [Cites] Int J Dev Neurosci. 1997 Oct;15(6):749-54 [9402225.001]
  • [Cites] DNA Res. 1997 Oct 31;4(5):307-13 [9455477.001]
  • [Cites] Brain Pathol. 1998 Jan;8(1):13-8 [9458162.001]
  • [Cites] Trends Neurosci. 1998 Sep;21(9):383-90 [9735946.001]
  • [Cites] J Immunol Methods. 1998 Jun 1;215(1-2):45-58 [9744747.001]
  • [Cites] Neuron. 1999 Jan;22(1):103-14 [10027293.001]
  • [Cites] Trends Biochem Sci. 1999 Jan;24(1):34-6 [10087920.001]
  • [Cites] Eur J Neurosci. 1999 Sep;11(9):3199-214 [10510184.001]
  • [Cites] Genes Dev. 2004 Nov 15;18(22):2724-9 [15545630.001]
  • [Cites] Dev Biol. 2005 Jan 15;277(2):366-77 [15617680.001]
  • [Cites] Nat Biotechnol. 2005 Jan;23(1):94-101 [15592455.001]
  • [Cites] EMBO J. 2005 Jan 26;24(2):240-50 [15635447.001]
  • [Cites] J Neurosci. 2005 Jan 26;25(4):869-79 [15673667.001]
  • [Cites] Brain Res Mol Brain Res. 2002 Sep 30;105(1-2):1-10 [12399102.001]
  • [Cites] Curr Opin Cell Biol. 2003 Feb;15(1):73-81 [12517707.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8452-9 [12482861.001]
  • [Cites] Am J Hum Genet. 2003 Apr;72(4):918-30 [12621583.001]
  • [Cites] Cerebellum. 2006;5(2):77-88 [16818382.001]
  • [Cites] Eur J Neurosci. 2006 Jul;24(2):466-78 [16903854.001]
  • [Cites] Cell. 2006 Oct 6;127(1):213-26 [17018287.001]
  • [Cites] J Biol Chem. 2006 Nov 17;281(46):35347-58 [17003044.001]
  • [Cites] Eur J Neurosci. 2006 Nov;24(9):2491-503 [17100838.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1337-47 [17115031.001]
  • [Cites] Mol Cell Neurosci. 2006 Dec;33(4):447-58 [17049261.001]
  • [Cites] Nature. 2007 Jan 11;445(7124):168-76 [17151600.001]
  • [Cites] Structure. 2007 Feb;15(2):145-55 [17292833.001]
  • [Cites] J Biol Chem. 2007 Mar 9;282(10):7624-31 [17224454.001]
  • [Cites] J Cell Biol. 2007 Mar 26;176(7):953-64 [17371834.001]
  • [Cites] Oncogene. 2007 Apr 5;26(16):2308-17 [17016438.001]
  • [Cites] Curr Biol. 2007 Jun 19;17(12):R455-7 [17580073.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13438-43 [10557339.001]
  • [Cites] J Mol Biol. 1999 Dec 17;294(5):1351-62 [10600390.001]
  • [Cites] J Mol Biol. 2000 Apr 14;297(5):1183-94 [10764582.001]
  • [Cites] Trends Neurosci. 2000 Aug;23(8):372-6 [10906801.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):433-73 [12663865.001]
  • [Cites] Biochem J. 2003 Apr 15;371(Pt 2):463-71 [12570871.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3625-30 [12824381.001]
  • [Cites] J Cell Biol. 2005 Jan 31;168(3):453-63 [15684034.001]
  • [Cites] J Comp Neurol. 2005 Mar 14;483(3):318-28 [15682397.001]
  • [Cites] Nat Rev Neurosci. 2005 Mar;6(3):201-14 [15711600.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2059-66 [15688017.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1153-62 [15793295.001]
  • [Cites] Cell Mol Life Sci. 2005 May;62(9):955-70 [15868099.001]
  • [Cites] Int J Oncol. 2005 Jun;26(6):1699-705 [15870888.001]
  • [Cites] Biochem J. 2005 Sep 15;390(Pt 3):641-53 [16134966.001]
  • [Cites] J Neurosci. 2005 Sep 14;25(37):8578-86 [16162939.001]
  • [Cites] J Cell Sci. 2005 Nov 15;118(Pt 22):5393-403 [16280553.001]
  • [Cites] Physiology (Bethesda). 2006 Feb;21:38-47 [16443821.001]
  • [Cites] Nat Methods. 2006 Mar;3(3):175-7 [16489333.001]
  • [Cites] PLoS Biol. 2006 Apr;4(4):e86 [16602821.001]
  • [Cites] Mol Cell. 2006 Jun 23;22(6):851-68 [16793553.001]
  • [Cites] Mol Biol Cell. 2006 Jul;17(7):3187-96 [16687575.001]
  • [Cites] J Neurosci. 2000 Aug 15;20(16):5899-905 [10934236.001]
  • [Cites] Nature. 2000 Dec 7;408(6813):732-5 [11130076.001]
  • [Cites] Cell. 2000 Dec 22;103(7):1001-4 [11163176.001]
  • [Cites] Nature. 2002 Jan 24;415(6870):436-42 [11807556.001]
  • [Cites] Nat Neurosci. 2002 Mar;5(3):239-46 [11850630.001]
  • [Cites] FEBS Lett. 2002 Feb 20;513(1):58-66 [11911881.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):291-4 [12082544.001]
  • [Cites] Dev Genes Evol. 2002 Sep;212(8):403-6 [12203097.001]
  • [Cites] Annu Rev Cell Dev Biol. 2002;18:601-35 [12142283.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3635-41 [12824383.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3709-11 [12824399.001]
  • [Cites] J Neurosci Res. 2003 Aug 1;73(3):400-9 [12868073.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):27981-7 [12695505.001]
  • [Cites] Cell. 2004 Jan 23;116(2):191-203 [14744431.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):14929-36 [14752106.001]
  • [Cites] Brain Res Dev Brain Res. 2004 Jun 21;150(2):177-90 [15158081.001]
  • [Cites] Nat Neurosci. 2004 Sep;7(9):923-9 [15286792.001]
  • [Cites] Neuron. 2004 Oct 14;44(2):321-34 [15473970.001]
  • [Cites] Cancer Lett. 2004 Nov 25;215(2):209-20 [15488640.001]
  • [Cites] Protein Eng Des Sel. 2004 Jun;17(6):527-36 [15314210.001]
  • [Cites] Development. 2004 Nov;131(22):5581-90 [15496441.001]
  • [Cites] J Neuropathol Exp Neurol. 1985 Nov;44(6):592-605 [4056828.001]
  • [Cites] Science. 1990 Apr 13;248(4952):223-6 [2109351.001]
  • [Cites] Neuroscience. 1993 Mar;53(1):121-30 [8097019.001]
  • [Cites] J Biol Chem. 1995 Apr 14;270(15):8730-8 [7721778.001]
  • (PMID = 17925019.001).
  • [ISSN] 1471-213X
  • [Journal-full-title] BMC developmental biology
  • [ISO-abbreviation] BMC Dev. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Microfilament Proteins; 0 / Mtss1 protein, mouse; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2194783
  •  go-up   go-down


50. Nagai A, Shibamoto Y, Mori Y, Hashizume C, Hagiwara M, Kobayashi T: Increases in the number of brain metastases detected at frame-fixed, thin-slice MRI for gamma knife surgery planning. Neuro Oncol; 2010 Nov;12(11):1187-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For gamma knife planning, 2.4-mm-slice MRIs are taken under rigid frame fixation, so tiny tumors become visible.
  • For gamma knife planning, spoiled gradient-recalled echo images were obtained after 0.1 mmol/kg gadolinium administration using a 1.5-T system.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Magnetic Resonance Imaging / methods. Surgery, Computer-Assisted / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Image Enhancement. Image Interpretation, Computer-Assisted / methods. Male. Middle Aged. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Clin Oncol. 2009 Aug;14(4):281-8 [19705237.001]
  • [Cites] Cancer. 2009 Feb 15;115(4):890-8 [19132728.001]
  • [Cites] J Neurooncol. 1999;44(3):275-81 [10720207.001]
  • [Cites] Zentralbl Neurochir. 1999;60(3):141-5 [10726337.001]
  • [Cites] Eur Radiol. 2001;11(1):117-22 [11194902.001]
  • [Cites] CNS Drugs. 2002;16(5):325-38 [11994022.001]
  • [Cites] Invest Radiol. 2003 Jul;38(7):415-22 [12821855.001]
  • [Cites] Neuro Oncol. 2003 Oct;5(4):268-74 [14565164.001]
  • [Cites] Radiology. 1981 May;139(2):397-402 [7220885.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Jul-Aug;11(4):785-91 [2114769.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Sep-Oct;11(5):967-74 [2121002.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Mar-Apr;12(2):293-300 [1902031.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Jan-Feb;13(1):335-45 [1595472.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Sep-Oct;13(5):1309-15; discussion 1316-8 [1414820.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Jun;15(6):1037-51 [8073972.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Feb;16(2):373-80 [7726087.001]
  • [Cites] Acta Radiol. 1995 May;36(3):300-6 [7742127.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 May;19(5):821-8 [9613494.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 May;19(5):829-30 [9613495.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1485-9 [9809728.001]
  • [Cites] Lung Cancer. 2004 Dec;46(3):357-60 [15541821.001]
  • [Cites] Lancet Neurol. 2005 May;4(5):289-98 [15847842.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):15-20 [16215812.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):31-42 [16215814.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1295-304 [16525185.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2483-91 [16757720.001]
  • [Cites] Eur J Neurol. 2006 Jul;13(7):674-81 [16834697.001]
  • [Cites] Cancer. 2008 Apr 15;112(8):1827-34 [18311784.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1168-73 [18495375.001]
  • [Cites] Neuro Oncol. 2010 Jul;12(7):711-9 [20156806.001]
  • (PMID = 20864500.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3098032
  •  go-up   go-down


51. Syse A, Loge JH, Lyngstad TH: Does childhood cancer affect parental divorce rates? A population-based study. J Clin Oncol; 2010 Feb 10;28(5):872-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS Data on the entire Norwegian married population, age 17 to 69 years, with children age 0 to 20 years in 1974 to 2001 (N = 977,928 couples) were retrieved from the Cancer Registry, the Central Population Register, the Directorate of Taxes, and population censuses.
  • An increased divorce rate was observed with Wilms tumor (odds ratio [OR], 1.52) but not with any of the other common childhood cancers.
  • Increased divorce rates were observed for couples in whom the mothers had an education greater than high school level (OR, 1.16); the risk was particularly high shortly after diagnosis, for CNS cancers and Wilms tumors, for couples with children 0 to 9 years of age at diagnosis, and after a child's death.
  • CONCLUSION This large, registry-based study shows that cancer in children is not associated with an increased parental divorce rate, except with Wilms tumors.
  • [MeSH-major] Divorce / psychology. Family Relations. Neoplasms / psychology. Stress, Psychological / etiology
  • [MeSH-minor] Adaptation, Psychological. Adolescent. Adult. Age of Onset. Aged. Child. Child, Preschool. Cost of Illness. Educational Status. Humans. Infant. Infant, Newborn. Logistic Models. Middle Aged. Neoplasm Staging. Norway / epidemiology. Odds Ratio. Population Surveillance. Prognosis. Registries. Risk Assessment. Risk Factors. Time Factors. Wilms Tumor / psychology. Young Adult


52. da Silva NS, Cappellano AM, Diez B, Cavalheiro S, Gardner S, Wisoff J, Kellie S, Parker R, Garvin J, Finlay J: Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study. Pediatr Blood Cancer; 2010 Mar;54(3):377-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study.
  • BACKGROUND: The treatment of central nervous system (CNS) germ cell tumors (GCT) remains controversial.
  • METHODS: Between January 2001 and December 2004 newly diagnosed patients with CNS GCT were treated with one of two risk-tailored chemotherapy regimens.
  • Twenty-five patients aged 4 months to 24.5 years were stratified: Regimen A consisted of 4-6 cycles of carboplatin/etoposide alternating with cyclophosphamide/etoposide for low risk (LR) localized germinoma with normal cerebrospinal fluid (CSF) and serum tumor markers.
  • Our results indicate that, at the present time, standard treatment for CNS GCT continues to include irradiation either alone or combined with chemotherapy for pure germinomas and with chemotherapy for those with MMGCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Carboplatin / adverse effects. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Infant. Male. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 20063410.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


53. Acciarri N, Galassi E, Giulioni M, Pozzati E, Grasso V, Palandri G, Badaloni F, Zucchelli M, Calbucci F: Cavernous malformations of the central nervous system in the pediatric age group. Pediatr Neurosurg; 2009;45(2):81-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cavernous malformations of the central nervous system in the pediatric age group.
  • OBJECTIVE: The main clinico-diagnostic features, risk factors and associated diseases of cavernous malformations (CMs), also called cavernous angiomas or cavernomas, of the central nervous system (CNS) in children are described, and the most relevant differences compared to the affected adult population are pointed out, focusing on the management of pediatric patients harboring cranial and spinal CMs.
  • The results were compared with those found in the most recent literature dealing with pediatric CMs of the CNS.
  • CONCLUSION: CMs represent the most common CNS vascular lesion in children, although their incidence is 4 times lower than that of the adult population.
  • The natural history of pediatric CMs throughout the neuraxis seems to be more aggressive than in adult patients; these lesions have higher rates of growth and hemorrhage, larger dimensions and often atypical radiological pictures at diagnosis.
  • Beside the familial form of the disease, which is more often associated with multiple lesions and an earlier age of clinical presentation, the major risk factor for CMs in children seems to be radiotherapy for CNS tumors.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / diagnosis. Hemangioma, Cavernous, Central Nervous System / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 S. Karger AG, Basel.
  • (PMID = 19307743.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


54. Schneider DT, Zahn S, Sievers S, Alemazkour K, Reifenberger G, Wiestler OD, Calaminus G, Göbel U, Perlman EJ: Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization. Mod Pathol; 2006 Jun;19(6):864-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization.
  • The limited information available to date regarding the genetic alterations in germ cell tumors of the central nervous system has raised concerns about their biologic relationship to other germ cell tumor entities.
  • We investigated fresh-frozen or archival tumor samples from 19 patients with central nervous system germ cell tumors (CNS-GCTs), including seven germinomas, eight malignant nongerminomatous germ cell tumors and four teratomas, using chromosomal comparative genomic hybridization to determine recurrent chromosomal imbalances.
  • All 15 malignant CNS-GCTs and two of four teratomas showed multiple chromosomal imbalances.
  • Chromosomal gains (median: 4 gains/tumor, range: 0-9 gains/tumor) were observed more frequently than losses (median: 1.6 losses/tumor, range: 0-6 losses/tumor).
  • Gain of 12p, which is considered characteristic for germ cell tumors of the adult testis, was detected in 11 of 19 tumors and 10 of 15 malignant CNS-GCTs.
  • In one tumor, gain of 12p was confined to an amplicon at 12p12, corresponding to the commonly amplified region on 12p.
  • Notably, we observed no difference in the genetic profiles of germinomatous and nongerminomatous CNS-GCTs; however, the average number of imbalances was higher in the latter group.
  • A meta-analysis comparing 116 malignant gonadal and extragonadal germ cell tumors revealed that the genomic alterations in CNS-GCTs are virtually indistinguishable from those found in their gonadal or other extragonadal counterparts of the corresponding age group.
  • These data strongly argue in favor of common pathogenetic mechanisms in gonadal and extragonadal germ cell tumors.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Genetic Testing / methods. Neoplasms, Germ Cell and Embryonal / genetics. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. DNA, Neoplasm / analysis. Female. Humans. Infant, Newborn. Male. Meta-Analysis as Topic

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607373.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


55. Lu NH, Chen CY, Chou JM, Kuo TH, Yeh CH: MR imaging of primary spinal germinoma: a case report and review of the literature. J Neuroimaging; 2009 Jan;19(1):92-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Germinomas in the central nervous system (CNS) are uncommon tumors and occur usually in the pineal or suprasellar regions.
  • Here we reported a rare case of an extramedullary germinoma in a young adult who presented with progressive paraparesis and retention of stool and urine.
  • [MeSH-major] Germinoma / diagnosis. Magnetic Resonance Imaging / methods. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Lumbar Vertebrae. Male. Thoracic Vertebrae. Young Adult

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798779.001).
  • [ISSN] 1552-6569
  • [Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging
  • [ISO-abbreviation] J Neuroimaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


56. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ: Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol; 2010 Sep 20;28(27):4221-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
  • PURPOSE: To estimate the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetic properties of lapatinib, a selective epidermal growth factor receptor (EGFR) and ERBB2 inhibitor, in children with refractory or recurrent CNS malignancies.
  • Expression of the four ERBB receptors and downstream signaling elements in tumor tissue was evaluated by immunohistochemistry.
  • Frequent, high-level expression of activated (phosphorylated) EGFR and ERBB2 receptors and downstream signal intermediates were observed in tumors, particularly in ependymomas that displayed prolonged stable disease on lapatinib therapy.
  • CONCLUSION: Lapatinib is well tolerated in children with recurrent CNS malignancies, with rash, diarrhea, and fatigue identified as DLTs.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Central Nervous System Neoplasms / drug therapy. Protein Kinase Inhibitors / administration & dosage. Quinazolines / administration & dosage
  • [MeSH-minor] Administration, Oral. Adolescent. Child. Child, Preschool. Diarrhea / chemically induced. Exanthema / chemically induced. Fatigue / chemically induced. Female. Humans. Infant. Male. Maximum Tolerated Dose. Phosphorylation. Receptor, Epidermal Growth Factor / analysis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, ErbB-2 / analysis. Receptor, ErbB-2 / antagonists & inhibitors. Steroids / therapeutic use. Treatment Outcome. United States. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Jan;65(2):353-61 [19499221.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6255-63 [12214266.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3054-64 [12374672.001]
  • [Cites] Mol Cancer Ther. 2001 Dec;1(2):85-94 [12467226.001]
  • [Cites] Lancet Oncol. 2003 Jul;4(7):397-406 [12850190.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3620-4 [14506149.001]
  • [Cites] Mol Cell. 2003 Sep;12(3):541-52 [14527402.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):984-93 [14970185.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):317-28 [15093539.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11 [15158434.001]
  • [Cites] Oncologist. 2004;9 Suppl 3:10-5 [15163842.001]
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1165-72 [2566907.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5305-13 [15955900.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 2;831(1-2):169-75 [16364699.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1630-9 [16452222.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 [16829981.001]
  • [Cites] Trends Cell Biol. 2006 Dec;16(12):649-56 [17085050.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2733-43 [17192538.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3137-43 [17634493.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3397-8 [17635950.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3753-8 [17704424.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1993-9 [18421051.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):286-97 [18544443.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4484-90 [18628463.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4921-7 [18794549.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1452-9 [19228746.001]
  • [Cites] J Biopharm Stat. 2009;19(3):437-55 [19384687.001]
  • [Cites] Clin Pharmacol Ther. 2000 Oct;68(4):356-66 [11061575.001]
  • (PMID = 20713864.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA129541; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCI NIH HHS / CA / U01CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / Steroids; 0VUA21238F / lapatinib; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2953974
  •  go-up   go-down


57. Zhang D, Hu LB, Henning TD, Ravarani EM, Zou LG, Feng XY, Wang WX, Wen L: MRI findings of primary CNS lymphoma in 26 immunocompetent patients. Korean J Radiol; 2010 May-Jun;11(3):269-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI findings of primary CNS lymphoma in 26 immunocompetent patients.
  • OBJECTIVE: To record the MR imaging features of primary central nervous system lymphoma (PCNSL) and compare these features in monofocal and multifocal disease.
  • Tumor location, tumor size, signal intensity, enhancement characteristics, age distribution, peritumoral edema, cystic changes, and the presence of calcifications were assessed.
  • Tumor size differed significantly between the two groups (t = 3.129, p < 0.01) and mildly or moderately enhanced lesions were more frequently found in the monofocal group (p < 0.05).
  • Monofocal PCNSL cases typically have larger sized tumors with mild or moderate enhancement.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Immunocompetence. Lymphoma / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Contrast Media. Female. Gadolinium DTPA. Humans. Image Enhancement / methods. Male. Middle Aged. Observer Variation. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 1999;16(1):29-35 [10532421.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):199-201 [10563423.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):219-26 [10563426.001]
  • [Cites] Neuroradiology. 1999 Nov;41(11):820-5 [10602854.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1427-33 [10751251.001]
  • [Cites] Neuroradiology. 2000 Oct;42(10):738-41 [11110076.001]
  • [Cites] AJR Am J Roentgenol. 2001 May;176(5):1319-26 [11312202.001]
  • [Cites] Eur Radiol. 2002 Feb;12(2):329-40 [11870430.001]
  • [Cites] Clin Neurol Neurosurg. 2003 Apr;105(2):78-86 [12691795.001]
  • [Cites] Clin Radiol. 1982 May 3;33(3):331-6 [7075140.001]
  • [Cites] Neuroradiology. 1984;26(6):485-92 [6504318.001]
  • [Cites] AJR Am J Roentgenol. 1986 Feb;146(2):271-6 [3484575.001]
  • [Cites] J Neurosurg. 1986 Nov;65(5):592-9 [3772444.001]
  • [Cites] Radiology. 1988 Apr;167(1):211-5 [3279454.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):835-53 [3286832.001]
  • [Cites] Neuroradiology. 1992;34(1):36-42 [1553036.001]
  • [Cites] Ann Neurol. 1993 Mar;33(3):308-11 [8498814.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1383-97 [8055462.001]
  • [Cites] Clin Radiol. 1994 Oct;49(10):696-702 [7955832.001]
  • [Cites] Radiology. 1995 Jan;194(1):271-6 [7997566.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):77-82 [7815138.001]
  • [Cites] AJR Am J Roentgenol. 1995 Sep;165(3):626 [7645482.001]
  • [Cites] Neuroradiology. 1996 Jan;38(1):34-7 [8773272.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Mar;18(3):563-72 [9090424.001]
  • [Cites] Ann Oncol. 1997 Mar;8(3):227-34 [9137790.001]
  • [Cites] Radiographics. 1997 Nov-Dec;17(6):1497-526 [9397461.001]
  • [Cites] Clin Radiol. 1998 Jun;53(6):428-34 [9651058.001]
  • [Cites] Neurochirurgie. 1997;43(6):385-7 [9706618.001]
  • [Cites] Clin Neurol Neurosurg. 2004 Dec;107(1):55-63 [15567554.001]
  • [Cites] AJR Am J Roentgenol. 2005 May;184(5):1679-85 [15855138.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):169-77 [15925998.001]
  • [CommentIn] Korean J Radiol. 2010 Nov-Dec;11(6):702-3 [21076600.001]
  • (PMID = 20461180.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ PMC2864853
  • [Keywords] NOTNLM ; Brain neoplasm / Computed tomography (CT) / Lymphoma / Magnetic resonance (MR)
  •  go-up   go-down


58. Kanno H, Yamamoto I, Nishikawa R, Matsutani M, Wakabayashi T, Yoshida J, Shitara N, Yamasaki I, Shuin T, Clinical VHL Research Group in Japan: Spinal cord hemangioblastomas in von Hippel-Lindau disease. Spinal Cord; 2009 Jun;47(6):447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among these 48 patients, 46 of them (95.8%) also had a central nervous system (CNS) hemangioblastoma at another site: 42 (87.5%) with cerebellar hemangioblastoma and 11 (22.9%) with brain stem hemangioblastoma.
  • The 48 patients with spinal cord hemangioblastomas collectively had a total of 74 tumors.
  • The tumor was accompanied with a syrinx in 64 and without it in 10 patients.
  • CONCLUSION: Von Hippel-Lindau disease patients bearing spinal cord hemangioblastomas mostly had a CNS hemangioblastoma at another site.
  • These tumors can be removed in the majority of VHL patients without aggravation.
  • [MeSH-major] Hemangioblastoma / etiology. Hemangioblastoma / surgery. Spinal Cord Neoplasms / etiology. Spinal Cord Neoplasms / surgery. von Hippel-Lindau Disease / complications
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Neurologic Examination. Retrospective Studies. Severity of Illness Index. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19030009.001).
  • [ISSN] 1476-5624
  • [Journal-full-title] Spinal cord
  • [ISO-abbreviation] Spinal Cord
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Ibayashi Y; Yamaki T; Numagami Y; Jokura E; Kayama Y; Yamada Y; Shiokawa Y; Yamashita J; Hasegawa M; Hatano H; Shinoda J; Sakai N; Taki W; Matsushima S; Murao K; Matsubara T; Takahashi JA; Matsumoto K; Nakajima H; Hashimoto M; Matsumoto S; Ichigizaki K; Murase I; Kashiwabara K; Yamakawa Y; Yamazaki H; Kubo S; Tokuda K; Abiko S; Miyazaki H; Anda T; Shibata S; Miyamoto T; Okawa N; Morimoto S; Inoue M; Miyagami M
  •  go-up   go-down


59. Vasudevan V, Cheung MC, Yang R, Zhuge Y, Fischer AC, Koniaris LG, Sola JE: Pediatric solid tumors and second malignancies: characteristics and survival outcomes. J Surg Res; 2010 May 15;160(2):184-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric solid tumors and second malignancies: characteristics and survival outcomes.
  • BACKGROUND: To examine the incidence, characteristics, and outcomes for second malignancies following the diagnosis of a primary solid tumor in pediatric patients.
  • Mean age at diagnosis of the primary tumor was 7.7 y.
  • The most common primary malignancies were CNS tumors (22.5%), followed by soft tissue sarcoma (15.8%), retinoblastoma (14.1%), and bone tumors (13%).
  • Hematologic malignancies (35.5%) were the most common second malignancies noted in the cohort, followed by bone tumors (18%) and soft tissue sarcomas (15%).
  • Hematologic malignancies had a shorter latency (3.1 y) compared with solid second tumors (11.6 y).
  • For most tumor categories, development of a secondary malignancy was associated with lower 5- and 10-y survival than expected.
  • CONCLUSIONS: CNS tumors, retinoblastoma, and soft tissue sarcomas in children are the most common solid primary tumors, with an increased risk of a second malignancy.
  • Leukemia is the most common second malignancy seen in pediatric solid tumors.
  • [MeSH-major] Neoplasms / mortality. Neoplasms, Second Primary / mortality. SEER Program
  • [MeSH-minor] Adolescent. Bone Neoplasms / mortality. Central Nervous System Neoplasms / mortality. Child. Child, Preschool. Female. Follow-Up Studies. Hematologic Neoplasms / mortality. Humans. Incidence. Male. Retinoblastoma / mortality. Sarcoma / mortality. Soft Tissue Neoplasms / mortality. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19765728.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Hosono A, Makimoto A, Kawai A, Takaue Y: Segregated graft-versus-tumor effect between CNS and non-CNS lesions of Ewing's sarcoma family of tumors. Bone Marrow Transplant; 2008 Jun;41(12):1067-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Segregated graft-versus-tumor effect between CNS and non-CNS lesions of Ewing's sarcoma family of tumors.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Graft vs Tumor Effect. Hematopoietic Stem Cell Transplantation / methods. Neoplasm Recurrence, Local / therapy. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adult. Female. Humans. Siblings. Transplantation, Homologous

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18332914.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


61. Koch SV, Kejs AM, Engholm G, Møller H, Johansen C, Schmiegelow K: Leaving home after cancer in childhood: a measure of social independence in early adulthood. Pediatr Blood Cancer; 2006 Jul;47(1):61-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The risk for leaving home of survivors of hematological malignancies and solid tumors did not differ significantly from that of the control cohort.
  • In contrast, survivors of central nervous system (CNS) tumors had a significantly reduced risk for leaving home, which was most pronounced for men (relative risk, men: 0.66; 95% confidence interval, 0.55-0.80; women: 0.88, 95% confidence interval, 0.80-0.97).
  • CONCLUSION: Overall, the psychosocial effects of cancer in childhood or adolescence and its treatment on the survivor and family did not appear to impede social independence in early adulthood, except for survivors of CNS tumors.
  • [MeSH-major] Life Change Events. Neoplasms / rehabilitation. Residence Characteristics. Social Adjustment. Survivors
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Child. Denmark. Female. Humans. Male. Proportional Hazards Models. Risk. Socioeconomic Factors

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16572415.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Sasayama T, Nishihara M, Tanaka K, Mizukawa K, Ehara K, Kanomata N, Kohmura E: Two metachronous tumors induced by radiation therapy: case report and review of the literature. J Neurooncol; 2008 Jul;88(3):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two metachronous tumors induced by radiation therapy: case report and review of the literature.
  • Various radiation-induced tumors, including meningioma, glioma, and sarcoma, have been reported; however, metachronous intracranial double tumors induced by radiation therapy are extremely rare.
  • A 1-year-old boy had undergone tumor removal and craniospinal radiation therapy (30 Gy) for cerebellar medulloblastoma.
  • Six years later, an infiltrative tumor was newly found in the right fronto-temporal white matter.
  • The patient underwent stereotactic biopsy, and the tumor was found to be an anaplastic astrocytoma.
  • Since both secondary tumors were located within the area of previous radiation and the patient did not have any genetic disease predisposing him to tumors, radiation therapy was considered to be responsible for their tumorigenesis.
  • To our knowledge, this case is the fourth case of radiation-induced double CNS tumors arising after radiotherapy to be described in the literature.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasms, Radiation-Induced / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Age of Onset. Cerebellar Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Humans. In Situ Hybridization, Fluorescence. Infant. Loss of Heterozygosity. Magnetic Resonance Imaging. Male. Medulloblastoma / radiotherapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):390-7 [10958546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):161-81 [15674476.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):73-7 [16292489.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):111-5 [9420081.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1002-13 [15200115.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):393-6 [9007876.001]
  • [Cites] Radiat Oncol. 2007 Jan 11;2:5 [17217530.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):143-6 [10729825.001]
  • [Cites] Childs Nerv Syst. 2006 Sep;22(9):1201-7 [16570196.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4091-5 [8508374.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):865-71 [9427429.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):436-45 [2995867.001]
  • [Cites] Neurol Res. 2007 Oct;29(7):723-6 [17553214.001]
  • [Cites] Neurosurgery. 1995 Apr;36(4):685-90 [7596497.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):763-70 [9810442.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):564-74 [1885974.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jul;59(7):614-20 [10901233.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Cancer Lett. 1999 Jan 29;135(2):223-8 [10096432.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):77-82 [2661743.001]
  • [Cites] Neurosurgery. 1996 May;38(5):915-24; discussion 924-5 [8727816.001]
  • (PMID = 18373066.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Swain RS, Tihan T, Horvai AE, Di Vizio D, Loda M, Burger PC, Scheithauer BW, Kim GE: Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor. Hum Pathol; 2008 Mar;39(3):410-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor.
  • Inflammatory myofibroblastic tumor (IMT) is a distinctive spindle cell lesion and occurs primarily in soft tissue.
  • IMT in the central nervous system (CNS) is rare, its characteristics are poorly defined, and its relation to similar tumors at other sites is unclear.
  • To better characterize IMT within the CNS, we studied clinicopathologic features of 6 IMTs and compared them with 18 nonneoplastic lesions originally classified as IP.
  • All tumors were composed of neoplastic spindle cells and a variable amount of inflammatory infiltrate.
  • We suggest that IMT in the CNS is distinct from the nonneoplastic IP, and distinguishing IMT from nonneoplastic lesions should enable better decisions for patient management.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Granuloma, Plasma Cell / classification. Granuloma, Plasma Cell / pathology. Myofibroma / classification. Myofibroma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Male. Middle Aged

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261625.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Beauchesne P, Bernier V, Carnin C, Taillandier L, Djabri M, Martin L, Michel X, Maire JP, Khalil T, Kerr C, Gorlia T, Stupp R, Pedeux R: Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy. Neuro Oncol; 2010 Jun;12(6):595-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ultrafractionation of radiation therapy is a novel regimen consisting of irradiating tumors several times daily, delivering low doses (<0.75 Gy) at which hyperradiosensitivity occurs.
  • Conformal irradiation included the tumor bulk with a margin of 2.5 cm.
  • No acute Grade III and/or IV CNS toxicity was observed.
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pilot Projects. Survival Rate / trends

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Radiat Ther Oncol. 1999;33:241-3 [10549493.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):649-52 [6164465.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):379-89 [11173131.001]
  • [Cites] Int J Radiat Biol. 2001 Jun;77(6):655-64 [11403705.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):33-40 [12672027.001]
  • [Cites] Acta Oncol. 2003;42(5-6):582-8 [14596516.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1976 Jul-Aug;1(7-8):639-44 [185170.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2301-6 [6291739.001]
  • [Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1986 Apr;49(4):565-80 [3485598.001]
  • [Cites] Radiother Oncol. 1987 May;9(1):21-6 [3037617.001]
  • [Cites] Front Radiat Ther Oncol. 1988;22:149-61 [3280411.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Nov;15(5):1091-5 [2846480.001]
  • [Cites] Br J Cancer. 1989 Mar;59(3):325-6 [2649133.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1389-96 [2542193.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] N Engl J Med. 1991 May 23;324(21):1471-6 [1822669.001]
  • [Cites] N Engl J Med. 1991 May 30;324(22):1555-64 [2027359.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Int J Radiat Biol. 1993 May;63(5):639-50 [8099110.001]
  • [Cites] Radiat Res. 1994 Apr;138(1 Suppl):S81-4 [8146334.001]
  • [Cites] Radiother Oncol. 1994 Jul;32(1):63-72 [7938680.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1535-43 [8608540.001]
  • [Cites] Int J Radiat Biol. 1996 Mar;69(3):279-90 [8613677.001]
  • [Cites] Int J Radiat Biol. 1997 Jun;71(6):721-35 [9246186.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5 [9422557.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):29-38 [18082451.001]
  • [Cites] Int J Radiat Biol. 1999 Nov;75(11):1341-8 [10597908.001]
  • (PMID = 20511183.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940649
  •  go-up   go-down


65. Sigauke E, Rakheja D, Maddox DL, Hladik CL, White CL, Timmons CF, Raisanen J: Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis. Mod Pathol; 2006 May;19(5):717-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis.
  • Malignant rhabdoid tumors are high-grade neoplasms of the central nervous system (CNS), kidneys and soft tissue that usually occur in children.
  • The histologic diagnosis of malignant rhabdoid tumor depends on identification of characteristic rhabdoid cells-large cells with eccentrically located nuclei and abundant, eosinophilic cytoplasm-and immunohistochemistry with antibodies to vimentin, keratin and epithelial membrane antigen.
  • In most malignant rhabdoid tumors, the SMARCB1/INI1 gene, located in chromosome band 22q11.2, is inactivated by deletions and/or mutations, so genetic diagnosis is often possible.
  • We assessed SMARCB1/INI1 expression in 17 rhabdoid tumors and 57 other tumors of the CNS, kidney or soft tissue using immunohistochemistry.
  • In total, 12 brain, three renal and two soft tissue rhabdoid tumors were examined along with four glioblastomas, four pilocytic astrocytomas, four oligodendrogliomas, two ependymomas, two choroid plexus papillomas, five pituitary adenomas, four germinomas, four renal carcinomas with Xp11.2 translocations, two clear cell sarcomas, two Wilms' tumors, one renal medullary carcinoma, two desmoplastic small round cell tumors, two alveolar rhabdomyosarcomas, two embryonal rhabdomyosarcomas, one low-grade chondrosarcoma, two extraskeletal myxoid chondrosarcomas, one mesenchymal chondrosarcoma, four malignant peripheral nerve sheath tumors, five metastatic carcinomas and four epithelioid sarcomas, two primary and two metastatic.
  • The neoplastic cells of all rhabdoid tumors, the four epithelioid sarcomas and the renal medullary carcinoma did not express SMARCB1/INI1 by immunohistochemistry; neoplastic cells of all other tumors expressed SMARCB1/INI1.
  • Immunohistochemistry to assess expression of SMARCB1/INI1 may be useful in the diagnosis of rhabdoid tumors of the CNS, kidneys and soft tissue.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. DNA-Binding Proteins / biosynthesis. Kidney Neoplasms / pathology. Rhabdoid Tumor / pathology. Soft Tissue Neoplasms / pathology. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Child. Child, Preschool. Chromosomal Proteins, Non-Histone. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Infant. Infant, Newborn. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528370.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


66. Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, Mavroudis D, Georgoulias V: Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. Breast Cancer Res; 2006;8(4):R36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.
  • INTRODUCTION: To evaluate the incidence of central nervous system (CNS) involvement in patients with breast cancer treated with a taxane-based chemotherapy regimen and to determine predictive factors for CNS relapse.
  • METHODS: The medical files of patients with early breast cancer (n = 253) or advanced stage breast cancer (n = 239) as well of those with other solid tumors (n = 336) treated with or without a taxane-based chemotherapy regimen during a 42-month period were reviewed.
  • HER2/neu overexpression was identified by immunohistochemistry, whereas cytokeratin 19 (CK-19) mRNA-positive circulating tumor cells (CTCs) in the peripheral blood were identified by real-time PCR.
  • RESULTS: The incidence of CNS relapse was similar in patients suffering from breast cancer or other solid tumors (10.4% and 11.4%, respectively; P = 0.517).
  • The incidence of CNS relapse was significantly higher in breast cancer patients with advanced disease (P = 0.041), visceral disease and bone disease (P = 0.036), in those who were treated with a taxane-containing regimen (P = 0.024), in those with HER2/neu-overexpressing tumors (P = 0.022) and, finally, in those with detectable CK-19 mRNA-positive CTCs (P = 0.008).
  • Multivariate analysis revealed that the stage of disease (odds ratio, 0.23; 95% confidence interval, 0.007-0.23; P = 0.0001), the HER2/neu status (odds ratio, 29.4; 95% confidence interval, 7.51-101.21; P = 0.0001) and the presence of CK-19 mRNA-positive CTCs (odds ratio, 8.31; 95% confidence interval, 3.97-12.84; P = 0.001) were independent predictive factors for CNS relapse.
  • CONCLUSION: CNS relapses are common among breast cancer patients treated with a taxane-based chemotherapy regimen, patients with HER2/neu-positive tumor and patients with CK-19 mRNA-positive CTCs.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / physiopathology. Central Nervous System Neoplasms / physiopathology. Neoplastic Cells, Circulating
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Humans. Keratin-19. Middle Aged. Neoplasm Staging. Predictive Value of Tests. RNA, Messenger. Receptor, ErbB-2 / biosynthesis. Taxoids / therapeutic use


67. Pećina-Slaus N, Niku Eva-Martić T, Beros V, Tomas D: Genetic alterations of E-cadherin and beta-catenin in germinoma and teratoma: report of two central nervous system cases. Pathol Oncol Res; 2007;13(4):370-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations of E-cadherin and beta-catenin in germinoma and teratoma: report of two central nervous system cases.
  • The genetic basis as well as mechanisms of development of germ cell tumors of the CNS are still unexplained.
  • In the present article changes of Ecadherin (CDH1) and beta-catenin (CTNNB1) genes in two CNS germ cell tumors are reported.
  • A case of germinoma of the central nervous system and a case of spinal channel teratoma were tested for loss of heterozygosity (LOH) of E-cadherin gene by PCR amplification of tetranucleotide polymorphism (D16S752).
  • Both germ cell tumors analyzed demonstrated LOH of the CDH1 gene.
  • Our findings may contribute to better understanding of the genetic profile of germ cell tumors.
  • [MeSH-major] Cadherins / genetics. Central Nervous System Neoplasms / genetics. Germinoma / genetics. Teratoma / genetics. beta Catenin / genetics
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Female. Humans. Loss of Heterozygosity. Male. Mutation. Pineal Gland / pathology. Pinealoma / genetics. Pinealoma / pathology. Spinal Cord Neoplasms / genetics. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Germinoma.
  • Genetic Alliance. consumer health - Teratoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1992 Feb;116(4):989-96 [1734027.001]
  • [Cites] Int J Cancer. 2002 Sep 10;101(2):198-201 [12209999.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):258-64 [9950496.001]
  • [Cites] Acta Neuropathol. 2006 Jun;111(6):563-8 [16718353.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1370-5 [16251967.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] J Pathol. 2004 Oct;204(2):167-74 [15378486.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23 (31):7951-7 [16258095.001]
  • [Cites] Nat Neurosci. 2003 Nov;6(11):1169-77 [14528308.001]
  • [Cites] J Cutan Pathol. 2007 Mar;34(3):239-46 [17302608.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):569-74 [17083471.001]
  • [Cites] Cancer Cell Int. 2003 Oct 14;3(1):17 [14613514.001]
  • [Cites] J Cell Biol. 1994 Dec;127(6 Pt 2):2061-9 [7806582.001]
  • [Cites] J Biol Chem. 1997 Oct 3;272(40):24735-8 [9312064.001]
  • [Cites] Curr Opin Neurobiol. 2000 Jun;10(3):392-9 [10851180.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):134-46 [10337997.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):139-51 [11550309.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12 ):1613-8 [17122519.001]
  • [Cites] Pediatr Dev Pathol. 2006 Mar-Apr;9(2):115-31 [16822086.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):445-9 [11433413.001]
  • [Cites] Int J Androl. 2006 Feb;29(1):219-27 [16466543.001]
  • [Cites] Neurosurg Rev. 2003 May;26(2):113-6 [12962297.001]
  • (PMID = 18158575.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin
  •  go-up   go-down


68. Lathia JD, Mattson MP, Cheng A: Notch: from neural development to neurological disorders. J Neurochem; 2008 Dec;107(6):1471-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Notch signaling plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation.
  • Notch is also present in post-mitotic neurons in the adult CNS wherein its activation influences structural and functional plasticity including processes involved in learning and memory.
  • Recent findings suggest that notch signaling in neurons, glia, and NSCs may be involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors.
  • Studies of animal models suggest the potential of agents that target notch signaling as therapeutic interventions for several different CNS disorders.
  • [MeSH-major] Central Nervous System / growth & development. Nervous System Diseases / metabolism. Nervous System Diseases / pathology. Neurons / physiology. Receptors, Notch / physiology

  • Genetic Alliance. consumer health - Neurological Disorders.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094054.001).
  • [ISSN] 1471-4159
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AG000314-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Notch
  • [Number-of-references] 115
  • [Other-IDs] NLM/ NIHMS106282; NLM/ PMC4544712
  •  go-up   go-down


69. Mühlisch J, Schwering A, Grotzer M, Vince GH, Roggendorf W, Hagemann C, Sörensen N, Rickert CH, Osada N, Jürgens H, Frühwald MC: Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood. Oncogene; 2006 Feb 16;25(7):1111-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood.
  • Supratentorial primitive neuroectodermal tumors (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of the CNS represent a biological and clinical enigma, despite advances in both molecular techniques and clinical management for these two rare embryonal brain tumors of childhood.
  • We thus studied aberrant methylation of the genes RASSF1A and CASP8 and its consequence on expression in cell lines and primary tumors using a combination of semiquantitative methylation specific PCR (MSP), bisulfite sequencing and RT-PCR.
  • A 5' CpG-rich region of CASP8 was methylated in normal tissues and in tumors.
  • However, CASP8 showed inconsistent expression patterns in normal and tumor tissues.
  • Our results indicate that aberrant methylation of the RASSF1A promoter region may be of importance in the origin and progression of sPNET and AT/RT while the analysed 5'-CpG rich region of the CASP8 gene does not seem to play an important role in these tumors.
  • Further studies of epigenetic changes in these rare tumors are warranted as their biology remains obscure and treatment efforts have been rather unsuccessfull.
  • [MeSH-major] Brain Neoplasms / genetics. DNA Methylation. Gene Silencing. Neuroectodermal Tumors, Primitive / genetics. Rhabdoid Tumor / genetics. Teratoma / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Caspase 8. Caspases / genetics. Child. Child, Preschool. CpG Islands. Epigenesis, Genetic. Female. Humans. Hydroxamic Acids / pharmacology. Infant. Male. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186793.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases; M801H13NRU / Azacitidine
  •  go-up   go-down


70. Kushner YB, Brimo F, Schwartzman K, Auger M: A rare case of pulmonary cryptococcal inflammatory myofibroblastic tumor diagnosed by fine needle aspiration cytology. Diagn Cytopathol; 2010 Jun;38(6):447-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of pulmonary cryptococcal inflammatory myofibroblastic tumor diagnosed by fine needle aspiration cytology.
  • In a recent outbreak in British Columbia (BC), Canada, Cryptococcus gattii, a rare species of Cryptococcus, was noted to affect primarily immunocompetent hosts and cause limited pulmonary or CNS disease.
  • We herein report a rare case of a pulmonary inflammatory myofibroblastic tumor caused by a Cryptococcus infection, presumed to be of the gattii species, in a 20-year-old immunocompetent college student from Vancouver, BC who presented with a large lung mass.
  • Cryptococcal inflammatory myofibroblastic tumors have been reported, but neither in the lung nor in the setting of an immunocompetent host.
  • [MeSH-minor] Antifungal Agents / therapeutic use. Biopsy, Fine-Needle. Cryptococcus gattii. Female. Fluconazole / therapeutic use. Humans. Young Adult

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19937947.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 8VZV102JFY / Fluconazole
  •  go-up   go-down


71. Brat DJ, Shehata BM, Castellano-Sanchez AA, Hawkins C, Yost RB, Greco C, Mazewski C, Janss A, Ohgaki H, Perry A: Congenital glioblastoma: a clinicopathologic and genetic analysis. Brain Pathol; 2007 Jul;17(3):276-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Congenital central nervous system (CNS) tumors are uncommon, accounting for 1% of all childhood brain tumors.
  • Tumors were seen by neuroimaging as large, complex cerebral hemispheric masses.
  • Tumors were either minimally immunoreactive (n = 3) or negative (n = 3) for EGFR.
  • They are genetically distinct from their adult counterparts and show a low frequency of known genetic alterations.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 9. Glioblastoma / genetics. Tumor Suppressor Protein p53 / genetics


72. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol; 2010 Jan;20(1):245-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
  • Here we investigate the capability of this antibody to differentiate wild type and mutated IDH1 protein in central nervous system (CNS) tumors by Western blot and immunohistochemistry.
  • In Western blot, anti-IDH1R132H mouse monoclonal antibody mIDH1R132H detected a specific band only in mutated tumors.
  • Immunohistochemistry of 345 primary brain tumors demonstrated a strong cytoplasmic and weaker nuclear staining in 122 cases.
  • Intriguing is the ability of mIDH1R132H to detect single infiltrating tumor cells.
  • The very high frequency and the distribution of this mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma World Health Organization (WHO) grade II from pilocytic astrocytoma or ependymoma.
  • Noteworthy is the discrimination of the infiltrating edge of tumors with IDH1 mutation from reactive gliosis.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / enzymology. Brain Neoplasms / genetics. Ependymoma / genetics. Glioma / enzymology. Glioma / genetics. Isocitrate Dehydrogenase / genetics. Isocitrate Dehydrogenase / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigen-Antibody Reactions. Blotting, Western. Child. Child, Preschool. Cloning, Molecular. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Mutation / genetics. Mutation / physiology. Protein Biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19903171.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


73. Labidi SI, Bachelot T, Ray-Coquard I, Mosbah K, Treilleux I, Fayette J, Favier B, Galy G, Blay JY, Guastalla JP: Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer; 2009 May;9(2):118-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series.
  • Central nervous system (CNS) metastases are a major concern in patients with stage IV breast cancer.
  • Recent studies have shown the efficacy of anti-vascular endothelial growth factor drugs on brain tumors, in particular glioblastoma, but none has explored their efficacy and tolerance in breast cancer patients with CNS metastases.
  • We report 4 cases of patients with CNS metastases treated with bevacizumab and paclitaxel.
  • All but 1 had previous whole-brain radiation therapy, performance status 0-2, and radiographic evidence of progressive CNS metastases.
  • Significant antitumor activity was observed, with 1 complete response and 3 partial responses in the CNS metastases.
  • No patient had extra-CNS progression.
  • This observed antitumor activity suggests efficiency of the combination of bevacizumab and paclitaxel and warrants further evaluation of this combination as an alternative option for the treatment of multiple CNS metastases in breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Neoplasms, Hormone-Dependent / metabolism. Paclitaxel / administration & dosage. Prognosis. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433393.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 2S9ZZM9Q9V / Bevacizumab; EC 2.7.10.1 / Receptor, ErbB-2; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


74. Dashti SR, Baharvahdat H, Spetzler RF, Sauvageau E, Chang SW, Stiefel MF, Park MS, Bambakidis NC: Operative intracranial infection following craniotomy. Neurosurg Focus; 2008;24(6):E10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There has been significant disagreement regarding the incidence of postoperative central nervous system (CNS) infections following cranial surgery.
  • In this paper the authors' goal was to perform a retrospective review of the incidence of CNS infection after cranial surgery at their institution.
  • METHODS: The authors reviewed the medical records and imaging studies in all patients who underwent a craniotomy or stereotactic drainage for CNS infection over the past 10 years.
  • Most craniotomies leading to subsequent infection were performed for tumors or other mass lesions (23 of 50 patients), followed by craniotomies for hemorrhage and vascular lesions.
  • [MeSH-major] Brain Diseases / etiology. Central Nervous System Bacterial Infections / etiology. Craniotomy / adverse effects. Postoperative Complications / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Abscess / etiology. Brain Abscess / microbiology. Brain Abscess / therapy. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18518740.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Terasaki M, Bouffet E, Katsuki H, Fukushima S, Shigemori M: Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors. Surg Neurol; 2008 Jan;69(1):46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
  • BACKGROUND: The aim of this study was to determine the response and toxicity of patients with recurrent or treatment-induced brain tumors to TMZ and oral VP-16.
  • METHODS: Eleven patients with recurrent or treatment-induced malignant CNS tumors, including treatment-induced PNET (in 1 patient), brainstem glioma (in 3 patients; 1 with treatment-induced, 2 with recurrence), recurrent anaplastic astrocytoma (in 3 patients), and recurrent glioblastoma (in 4 patients) were evaluated in a pilot study of TMZ and oral VP-16 chemotherapy.
  • The histologic subtype of the tumor, its location, and its maximum response to chemotherapy did not have an impact on the duration of disease control.
  • CONCLUSION: This limited pilot study confirms the innocuousness and the activity of the combination of TMZ and oral VP-16 in recurrent malignant brain tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Neuroepithelial / drug therapy. Neoplasms, Second Primary / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Pilot Projects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18054615.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


76. Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL: Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer; 2010 Jul 15;55(1):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation.
  • BACKGROUND: The purpose of this study was to evaluate a reduced irradiation dose strategy for newly diagnosed primary central nervous system (CNS) germinomas.
  • Initial tumor markers for beta-human chorionic gonadotrophin (HCGbeta) and alpha-fetoprotein (AFP) were evaluated in serum and lumbar cerebrospinal fluid (CSF).
  • RESULTS: Eighteen of 20 patients are without evidence of residual or recurrent tumor.
  • Both relapsing patients were subsequently determined to harbor malignant non-germinomatous germ cell tumor (NGGCT).
  • CONCLUSION: Chemotherapy followed by reduced dose whole ventricular and local boost irradiation appears to be effective in patients with localized pure CNS germinoma with evidence of preservation of neurocognitive function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Central Nervous System Neoplasms / therapy. Germinoma / therapy. Neoplasms, Germ Cell and Embryonal / therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / adverse effects. Carboplatin / therapeutic use. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Dose-Response Relationship, Radiation. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Young Adult. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20222020.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


77. Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C, Burns DK, Bajenaru ML, Gutmann DH, Parada LF: Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development; 2005 Dec;132(24):5577-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.
  • The gene responsible for neurofibromatosis type 1 (NF1) encodes a tumor suppressor that functions as a negative regulator of the Ras proto-oncogene.
  • Individuals with germline mutations in NF1 are predisposed to the development of benign and malignant tumors of the peripheral and central nervous system (CNS).
  • Children with this disease suffer a high incidence of optic gliomas, a benign but potentially debilitating tumor of the optic nerve; and an increased incidence of malignant astrocytoma, reactive astrogliosis and intellectual deficits.
  • In the present study, we have sought insight into the molecular and cellular basis of NF1-associated CNS pathologies.
  • We show that mice genetically engineered to lack NF1 in CNS exhibit a variety of defects in glial cells.
  • Primary among these is a developmental defect resulting in global reactive astrogliosis in the adult brain and increased proliferation of glial progenitor cells leading to enlarged optic nerves.
  • These data point to hyperproliferative glial progenitors as the source of the optic tumors and provide a genetic model for NF1-associated astrogliosis and optic glioma.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):361-7 [10931370.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):759-67 [11005256.001]
  • [Cites] J Neurosci. 2005 Jun 8;25(23):5584-94 [15944386.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7773-9 [15520182.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):38-44 [10469435.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4450-9 [10442636.001]
  • [Cites] Neuron. 2000 May;26(2):533-41 [10839371.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1433-8 [10688783.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):557-64 [16069817.001]
  • [Cites] Development. 2000 Dec;127(24):5253-63 [11076748.001]
  • [Cites] Neuron. 2000 Oct;28(1):69-80 [11086984.001]
  • [Cites] Nature. 2001 Feb 8;409(6821):714-20 [11217860.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] Nat Rev Neurosci. 2001 Apr;2(4):287-93 [11283751.001]
  • [Cites] Neurology. 2001 Apr 10;56(7):885-90 [11294925.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):859-76 [11297510.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]
  • [Cites] Genesis. 2001 Oct;31(2):85-94 [11668683.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):112-7 [11689956.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2085-91 [11929829.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5100-13 [12077339.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] J Neurosci. 2002 Nov 1;22(21):9228-36 [12417648.001]
  • [Cites] Neuron. 2003 Mar 6;37(5):751-64 [12628166.001]
  • [Cites] J Neurosci. 2003 Aug 6;23(18):7207-17 [12904481.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8573-7 [14695164.001]
  • [Cites] Neuron. 2004 Mar 25;41(6):881-90 [15046721.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Cell. 1990 Nov 16;63(4):835-41 [2121369.001]
  • [Cites] Cell. 1990 Nov 16;63(4):851-9 [2121371.001]
  • [Cites] Neuron. 1992 Mar;8(3):415-28 [1550670.001]
  • [Cites] Dev Dyn. 1992 Nov;195(3):216-26 [1301085.001]
  • [Cites] Dev Biol. 1994 Feb;161(2):538-51 [8314000.001]
  • [Cites] Neuron. 1994 Apr;12(4):895-908 [8161459.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Genes Dev. 1994 May 1;8(9):1019-29 [7926784.001]
  • [Cites] Development. 1994 Sep;120(9):2637-49 [7956838.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jul;54(4):588-600 [7602332.001]
  • [Cites] J Cell Biol. 1995 Oct;131(2):453-64 [7593171.001]
  • [Cites] Development. 1995 Nov;121(11):3583-92 [8582272.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):862-72 [9001241.001]
  • [Cites] Ann Neurol. 1997 Feb;41(2):143-9 [9029062.001]
  • [Cites] Trends Neurosci. 1997 Dec;20(12):570-7 [9416670.001]
  • [Cites] Cell. 1998 Sep 18;94(6):703-14 [9753318.001]
  • [Cites] Brain Res. 1999 Jan 16;816(1):111-23 [9878702.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] J Neurosci. 1999 Feb 1;19(3):1049-61 [9920668.001]
  • (PMID = 16314489.001).
  • [ISSN] 0950-1991
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS052606-01; United States / NINDS NIH HHS / NS / P50 NS052606; United States / NINDS NIH HHS / NS / P50 NS052606-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurofibromin 1
  • [Other-IDs] NLM/ NIHMS149022; NLM/ PMC2760350
  •  go-up   go-down


78. Freeman BB 3rd, Daw NC, Geyer JR, Furman WL, Stewart CF: Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest; 2006 Apr-May;24(3):310-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.
  • EGFR expression has been noted in neuroblastoma and rhabdomyosarcoma cell lines and in tumor specimens from children with Wilms tumor, osteosarcoma, and glioma.
  • Thus, gefitinib, the first marketed EGFR tyrosine kinase inhibitor, was chosen for study in children with refractory solid tumors and central nervous system (CNS) malignancies.
  • This review discusses findings from 3 clinical trials of gefitinib in children with refractory solid tumors and CNS malignancies, focusing on the clinical pharmacology of the compound.
  • Finally, the future for the use of gefitinib in pediatrics is similar to that of other molecularly targeted agents and awaits definition of tumors and patient populations in which it will be most advantageous.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Child. Clinical Trials as Topic. Drug Resistance, Neoplasm. Humans. Receptor, Epidermal Growth Factor / drug effects. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809160.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 7673326042 / irinotecan; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 67
  •  go-up   go-down


79. de Boer AG, Verbeek JH, van Dijk FJ: Adult survivors of childhood cancer and unemployment: A metaanalysis. Cancer; 2006 Jul 1;107(1):1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult survivors of childhood cancer and unemployment: A metaanalysis.
  • The purpose of this metaanalysis was to assess the risk of unemployment of adult survivors of childhood cancer compared with healthy controls and to explore prognostic factors.
  • Survivors of central nervous system (CNS) and brain tumors were nearly 5 times more likely to be unemployed (OR 4.74, 95% CI, 1.21-18.65), whereas the risks for survivors of blood or bone cancers were elevated but not found to be statistically significant (OR 1.42, 95% CI, 0.79-2.55; OR 1.97, 95% CI, 0.88-4.40, respectively).
  • Adult survivors of childhood cancer are at risk of unemployment, especially the subgroup of survivors of CNS and brain tumors.
  • [MeSH-major] Neoplasms / epidemiology. Survivors. Unemployment / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Europe. Female. Follow-Up Studies. Humans. Male. Odds Ratio. Prognosis. Retrospective Studies. Risk. Risk Factors. Time. United States

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • [CommentIn] Cancer. 2006 Dec 15;107(12):2958-9; author reply 2959 [17096430.001]
  • (PMID = 16718655.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


80. Asthagiri AR, Mehta GU, Zach L, Li X, Butman JA, Camphausen KA, Lonser RR: Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease. Neuro Oncol; 2010 Jan;12(1):80-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the effectiveness of stereotactic radiosurgery (SRS) treatment to central nervous system (CNS) hemangioblastomas in von Hippel-Lindau disease (VHL), we analyzed long-term results in VHL patients treated with SRS.
  • Patients were enrolled in a prospective VHL natural history study, undergoing SRS treatment of CNS hemangioblastomas.
  • Twenty VHL patients (10 males and 10 females) underwent SRS treatment of 44 CNS hemangioblastomas (39 cerebellar and 5 brainstem).
  • Mean treated tumor volume was 0.5 +/- 0.7 cm(3) (range: 0.01-3.6 cm(3)).
  • Mean prescription dose was 18.9 Gy (range: 12-24 Gy) at the tumor margin.
  • Univariate analysis did not identify variables associated (P > .05) with worse tumor control at last follow-up.
  • Thirty-three percent of SRS-treated small (<1.0 cm diameter), asymptomatic tumors progressed over a long-term follow-up.
  • These results indicate that SRS should not be used to prophylactically treat asymptomatic tumors and should be reserved for the treatment of tumors that are not surgically resectable.

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 2000;142(6):641-4; discussion 644-5 [10949438.001]
  • [Cites] Neurosurgery. 2008 Sep;63(3):443-50; discussion 450-1 [18812955.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):95-105 [12546357.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):106-16 [12546358.001]
  • [Cites] Lancet. 2003 Jun 14;361(9374):2059-67 [12814730.001]
  • [Cites] J Neurosurg. 2003 Jul;99(1 Suppl):64-9 [12859062.001]
  • [Cites] Nature. 1988 Mar 17;332(6161):268-9 [2894613.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 May;18(5):1165-71 [2347723.001]
  • [Cites] Lancet. 1991 May 4;337(8749):1052-4 [1673491.001]
  • [Cites] J Comput Assist Tomogr. 1992 Jul-Aug;16(4):519-28 [1629407.001]
  • [Cites] Science. 1993 May 28;260(5112):1317-20 [8493574.001]
  • [Cites] Surg Neurol. 1993 Nov;40(5):424-8 [8211662.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):493-9 [8655372.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):591-6 [8814161.001]
  • [Cites] Br J Neurosurg. 1997 Apr;11(2):110-5 [9155996.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):28-34; discussion 34-5 [9657185.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:179-86 [9782249.001]
  • [Cites] Am J Med. 1964 Apr;36:595-617 [14142412.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:97-101 [15662788.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:171-4 [15662804.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:225-9 [15662815.001]
  • [Cites] Br J Neurosurg. 2004 Aug;18(4):338-42 [15702831.001]
  • [Cites] Ann Neurol. 2005 Sep;58(3):392-9 [16130092.001]
  • [Cites] J Med Genet. 2006 Apr;43(4):289-94 [16155191.001]
  • [Cites] J Neurosurg. 2006 Aug;105(2):248-55 [17219830.001]
  • [Cites] Acta Neurochir (Wien). 2007 Oct;149(10):1007-13; discussion 1013 [17712513.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):210-22 [18240914.001]
  • [Cites] JAMA. 2008 Sep 17;300(11):1334-42 [18799446.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):82-94 [12546356.001]
  • (PMID = 20150370.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2940550
  •  go-up   go-down


81. Mehta GU, Asthagiri AR, Bakhtian KD, Auh S, Oldfield EH, Lonser RR: Functional outcome after resection of spinal cord hemangioblastomas associated with von Hippel-Lindau disease. J Neurosurg Spine; 2010 Mar;12(3):233-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To better define expected outcome and optimal management of these tumors in the context of this neoplasia syndrome, the authors analyzed the findings from patients with VHL disease who underwent resection of spinal cord hemangioblastomas.
  • One hundred forty-six operations (94%) were performed for symptom-producing tumors.
  • Complete resection was achieved for 217 tumors (99.5%).
  • Ventral tumors (OR 15.66, 95% CI 2.54-96.45; p = 0.003) or completely intramedullary tumors (OR 10.74, 95% CI 2.07-55.66; p = 0.005) were associated with an increased risk of postoperative worsening.
  • Long-term functional decline was caused by extensive VHL-associated CNS disease (6 patients), VHL-associated visceral disease (1 patient), or non-VHL disease (2 patients).
  • Tumor location (ventral or completely intramedullary) can be used to assess functional risk associated with surgery.
  • [MeSH-major] Hemangioblastoma / surgery. Spinal Cord / surgery. Spinal Cord Neoplasms / surgery. von Hippel-Lindau Disease / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neurologic Examination. Neurosurgical Procedures / methods. Postoperative Complications. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20192620.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


82. Kurwale NS, Ahmad FU, Satyarthi G, Suri A, Mahapatra AK: Can radiation induce pituitary tumors? Giant prolactinoma after radiation exposure. J Clin Neurosci; 2008 Nov;15(11):1287-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can radiation induce pituitary tumors? Giant prolactinoma after radiation exposure.
  • Radiation is a well-known etiology for many CNS tumors, including meningiomas, sarcomas and gliomas.
  • The role of radiation exposure in the etiology of pituitary adenoma is discussed, along with a literature review of radiation-induced tumors.
  • [MeSH-major] Neoplasms, Radiation-Induced. Pituitary Neoplasms / etiology. Prolactinoma / etiology. Radiotherapy, High-Energy / adverse effects
  • [MeSH-minor] Brain Stem Neoplasms / radiotherapy. Glioma / radiotherapy. Humans. Magnetic Resonance Imaging / methods. Male. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829328.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


83. Tehrani M, Friedman TM, Olson JJ, Brat DJ: Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol; 2008 Apr;18(2):164-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma.
  • We investigated whether intravascular thrombosis was more frequent or prominent in GBM than other central nervous system (CNS) malignancies and considered its prognostic significance in anaplastic astrocytoma (AA; WHO grade III), which lacks necrosis.
  • Histologic sections were examined for thrombosis, necrosis and microvascular hyperplasia from each of 297 CNS tumors, including 103 GBMs, 46 AAs, 20 diffuse astrocytoma (DAs; WHO grade II), eight anaplastic oligodendrogliomas (AOs; WHO grade III), 20 oligodendrogliomas (ODs; WHO grade II), 49 metastatic carcinomas (METs), 31 primary central nervous system lymphomas (PCNSLs) and 20 medulloblastomas (MBs).
  • Among newly diagnosed tumors, thrombosis was present in 92% of GBM resections, significantly greater than other types of CNS malignancies.
  • Of tumors with thrombosis, GBMs had a higher frequency of affected vessels than AAs, DAs, AOs, ODs and MBs, but had a frequency similar to METs and PCNSLs.
  • The sensitivity of thrombosis for the diagnosis of GBM in this set of tumors was 92% and the specificity was 91%.
  • Thus, intravascular thrombosis is more frequent in GBM than other CNS malignancies.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10643-6 [17108099.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 May;62(2):126-36 [17293122.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1949 Feb 2;24(3):71-5 [18111063.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Thromb Res. 2001 Jun 15;102(6):V215-24 [11516455.001]
  • [Cites] Curr Opin Pulm Med. 2001 Sep;7(5):326-31 [11584184.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):480-6 [1899696.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):375-80; discussion 380-1 [7731519.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1161-6 [8635139.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):115-8 [8958516.001]
  • [Cites] J Pathol Bacteriol. 1954 Jul;68(1):231-3 [13212575.001]
  • [Cites] Acta Pathol Microbiol Scand. 1950;27(1):51-64 [15406242.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1406-13 [15735028.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S62-7 [11927290.001]
  • [Cites] Clin Biochem. 2002 Jun;35(4):321-5 [12135696.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):2-12; discussion 12-3 [12182418.001]
  • [Cites] Ann Intern Med. 2003 Apr 15;138(8):659-68 [12693889.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1147-52 [15001257.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):397-405 [14990981.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):550-4 [6305479.001]
  • [Cites] Cancer. 1987 May 1;59(9):1617-25 [3030531.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • (PMID = 18093251.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS053727-01; United States / NINDS NIH HHS / NS / R01 NS053727; United States / NINDS NIH HHS / NS / NS053727; United States / NINDS NIH HHS / NS / R01 NS053727-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS82090; NLM/ PMC2610479
  •  go-up   go-down


84. Banerjee J, Pääkkö E, Harila M, Herva R, Tuominen J, Koivula A, Lanning M, Harila-Saari A: Radiation-induced meningiomas: a shadow in the success story of childhood leukemia. Neuro Oncol; 2009 Oct;11(5):543-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cranially irradiated survivors are predisposed to the development of CNS tumors.
  • Our aim was to describe the incidence of secondary brain tumors and to define the significance of treatment-related risk factors and host characteristics in a cohort of childhood leukemia survivors.
  • Our cohort consisted of 60 consecutive cranially irradiated adult survivors of childhood leukemia treated in Oulu University Hospital (Oulu, Finland); MRI of the brain was performed on 49.
  • The sites of the tumors, their histology, and details of the leukemia treatment were determined.
  • Of the 49 patients, 11 (22%) 1-8 years of age at the time of diagnosis developed meningioma later in life, while no other brain tumors were seen.
  • [MeSH-major] Leukemia / radiotherapy. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Child. Child, Preschool. Combined Modality Therapy. Humans. Incidence. Infant. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Risk Factors. Survivors / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 May 1;95(9):2770-5 [10779419.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):182-4 [18577989.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2267-75 [11187918.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):218-21 [11668501.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4257-64 [12036851.001]
  • [Cites] Cancer. 2003 May 15;97(10):2588-96 [12733158.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Br J Neurosurg. 2003 Jun;17(3):219-25 [14565516.001]
  • [Cites] J Adolesc Health. 2004 Apr;34(4):324-9 [15041002.001]
  • [Cites] Cancer. 1981 Mar 1;47(5 Suppl):1081-90 [7237365.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):339-47 [2822073.001]
  • [Cites] Childs Nerv Syst. 1989 Jun;5(3):135-9 [2758424.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] Acta Paediatr Scand. 1991 Dec;80(12):1220-8 [1785295.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4091-5 [8508374.001]
  • [Cites] Neuroradiology. 1994 Nov;36(8):652-5 [7862289.001]
  • [Cites] N Engl J Med. 1995 Jun 15;332(24):1618-30 [7753142.001]
  • [Cites] Br J Neurosurg. 1995;9(5):629-37 [8561935.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):318-22 [8707402.001]
  • [Cites] Lancet. 1997 May 10;349(9062):1369 [9149706.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2848-53 [9704738.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] J Radiat Res. 1999 Mar;40(1):49-57 [10408177.001]
  • [Cites] Br J Ophthalmol. 1953 Dec;37(12):758-62 [13115610.001]
  • [Cites] Neurology. 2005 Jan 25;64(2):350-2 [15668439.001]
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):617-21 [15799195.001]
  • [Cites] Cancer. 2005 Dec 1;104(11 Suppl):2557-64 [16247780.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37 [17077355.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):480-7 [17630615.001]
  • [Cites] Pediatr Blood Cancer. 2007 Sep;49(3):294-7 [17243137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]
  • (PMID = 19179425.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2765343
  •  go-up   go-down


85. Murray G, Jiménez L, Báez F, Colón-Castillo LE, Brau RH: Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico. P R Health Sci J; 2009 Dec;28(4):317-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico.
  • INTRODUCTION: Published studies regarding the incidence of central nervous system (CNS) tumors in Puerto Rico (PR) are exceedingly rare.
  • The general understanding is that the incidence of these tumors in Puerto Rico is similar to the one found in the United States of America (USA).
  • The objective of this study is to describe the specific profile of all the CNS tumors that are surgically intervened in Puerto Rico, through the creation of a database.
  • METHODS: A retrospective analysis of all the surgical procedures from January 1, 2002 to May 31, 2006 for adult CNS tumors in Puerto Rico was performed.
  • The information was organized to form a database of all the CNS neoplasms.
  • RESULTS: A total of 1,018 procedures for CNS tumors were performed on 1,005 patients.
  • The incidence rate of surgically intervened CNS tumors in Puerto Rico is 6 per 100,000 people.
  • CNS tumors were more common in women than in men (58% vs. 42%), respectively.
  • CONCLUSIONS: Our results reflect a unique histopathological distribution of operated CNS tumors in Puerto Rico.
  • In this series, primary tumors are more common than metastatic tumors.
  • Benign histological tumors were more frequent than more malignant variants.
  • Although this study reflects only the histologically diagnosed tumors, it is headway towards diagnosing the incidence of all CNS tumors in Puerto Rico.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Puerto Rico. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999240.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


86. Rousseau A, Kujas M, Bergemer-Fouquet AM, van Effenterre R, Hauw JJ: Survivin expression in ganglioglioma. J Neurooncol; 2006 Apr;77(2):153-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gangliogliomas are unusual central nervous system (CNS) neoplasms occurring mainly in children and young adults and inducing chronic pharmacoresistant epilepsy.
  • These are usually well differentiated neuroepithelial tumors composed of neurons in association with neoplastic glial cells.
  • Ten lesions were low-grade neoplasms whereas 5 were high-grade tumors.
  • Two additional tumors expressed survivin upon relapse.
  • Extended lifespan in survivin expressing cells might enhance aggressive behavior in these tumors through accumulation of mutations, thereby allowing progression to malignant phenotypes.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Ganglioglioma / metabolism. Ganglioglioma / pathology. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunohistochemistry. Infant. Inhibitor of Apoptosis Proteins. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Jul 1;101(1):146-55 [15222000.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1921-5 [10961895.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):173-83 [12241112.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1038-43 [9588548.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jul;54(4):513-20 [7541447.001]
  • [Cites] J Neurooncol. 2005 May;72(3):231-8 [15937645.001]
  • [Cites] Gut. 2000 May;46(5):645-50 [10764707.001]
  • [Cites] J Neurosurg. 2001 Jul;95(1):138-42 [11453385.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):989-1003 [9041162.001]
  • [Cites] J Neurosurg. 1992 Aug;77(2):302-6 [1625019.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7494-506 [15326475.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):1994-2007 [15688031.001]
  • [Cites] J Neurosurg. 1996 Jun;84(6):1055-9 [8847572.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1063-8 [11844831.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2229-37 [15512811.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jul;61(7):575-84 [12125736.001]
  • [Cites] Surg Neurol. 2000 Apr;53(4):360-8; discussion 368-9 [10825522.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):43-9 [9422522.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Dec;57(12):1497-502 [7798980.001]
  • [Cites] J Neurooncol. 2005 May;72(3):203-8 [15937641.001]
  • [Cites] Epilepsia. 1993 Jul-Aug;34(4):609-15 [8330569.001]
  • [Cites] Pediatr Neurosurg. 1992;18(5-6):310-4 [1476942.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):359-65 [15655550.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1757-65 [11337373.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1077-83 [12569609.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2100-4 [10561264.001]
  • [Cites] J Neurooncol. 2002 Mar;57(1):59-66 [12125968.001]
  • [Cites] J Neurosurg. 1993 Dec;79(6):859-66 [8246054.001]
  • [Cites] Jpn J Cancer Res. 2000 Nov;91(11):1204-9 [11092988.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):127-31 [8988736.001]
  • [Cites] J Neurosurg. 1993 Dec;79(6):867-73 [8246055.001]
  • [Cites] Acta Neuropathol. 1994;88(2):166-73 [7985497.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):127-34 [10656440.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):393-8 [10666367.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):305-10 [11352303.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):565-71 [9250169.001]
  • [Cites] Ann Pathol. 2001 Feb;21(1):55-8 [11223561.001]
  • [Cites] Am J Clin Oncol. 1998 Dec;21(6):557-64 [9856655.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):46-54 [12509766.001]
  • (PMID = 16292482.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


87. Nishihara H, Ozaki Y, Ito T, Yoshinaga T, Tabu K, Tanino M, Nagashima K, Tanaka S: A case of cerebral ganglioneuronal tumor in the parietal lobe of an adult. Brain Tumor Pathol; 2008;25(1):45-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of cerebral ganglioneuronal tumor in the parietal lobe of an adult.
  • Central nervous system (CNS) neuroblastoma/ganglioneuroblastoma is one of the embryonal tumors with neuronal differentiation found in young adults, but it is most common in children, especially in those below the age of 5 years, whereas extraventricular neurocytoma, a rare neuroepithelial tumor with neuronal differentiation, mostly affects young adults.
  • Here we present a rare case of cerebral ganglioneuronal tumor that occurred in a 32-year-old woman.
  • The patient suffered from tonic convulsion, and computed tomography demonstrated a well-demarcated, round tumor 3.3 cm in size with marked calcification in the right parietal lobe.
  • Immunohistochemically, the tumor cells did not react with any neuronal molecules, except for chromogranin A in ganglion-like large tumor cells, but electron microscopy demonstrated the presence of synapse-like nerve terminal structures without mature postsynaptic density, suggesting the presence of neoplastic tumor components with neuronal differentiation; thus, this tumor was diagnosed as CNS ganglioneuroblastoma with possible low-grade malignancy because the Mib-1 labeling index was less than 3%-4%.
  • Here we discuss the histological entity of cerebral ganglioneuronal tumors, including extraventricular neurocytoma.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioneuroblastoma / pathology. Parietal Lobe / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18415666.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


88. Watson DJ, Walton RM, Magnitsky SG, Bulte JW, Poptani H, Wolfe JH: Structure-specific patterns of neural stem cell engraftment after transplantation in the adult mouse brain. Hum Gene Ther; 2006 Jul;17(7):693-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structure-specific patterns of neural stem cell engraftment after transplantation in the adult mouse brain.
  • Transplantation of neural stem cells (NSCs) may be useful for delivering exogenous gene products to the diseased CNS.
  • Much of the prior work on NSC migration in the adult brain has examined directed migration within or toward focal areas of injury such as ischemia, brain tumors, or 6-hydroxydopamine (6-OHDA) lesions.
  • However, treatment of many genetic disorders that affect the CNS will require widespread dissemination of the donor cells in the postnatal brain, because the lesions are typically distributed globally.
  • We therefore tested the ability of NSCs to migrate in the unlesioned adult mouse brain after stereotaxic transplantation into several structures including the cortex and hippocampus.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FERRIC OXIDE .
  • Hazardous Substances Data Bank. HEMATITE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16839269.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK42707; United States / NIDDK NIH HHS / DK / DK46637; United States / NINDS NIH HHS / NS / NS07810; United States / NINDS NIH HHS / NS / NS11024; United States / NINDS NIH HHS / NS / NS38690; United States / NINDS NIH HHS / NS / NS45062
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferric Compounds; 1K09F3G675 / ferric oxide
  •  go-up   go-down


89. Kletzel M, Pirich L, Haut P, Cohn RA: Comparison of Tc-99 measurement of glomerular filtration rate vs. calculated creatinine clearance to assess renal function pretransplant in pediatric patients undergoing hematopoietic stem cell transplantation. Pediatr Transplant; 2005 Oct;9(5):584-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnoses included leukemia (n = 43), solid tumor (n = 27), bone marrow failure syndrome (n = 12), non-malignant disease (n = 8), CNS tumors (n = 5) and immunodeficiency (n = 3).
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Kidney Function Tests. Male. Renal Insufficiency / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Creatinine.
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16176414.001).
  • [ISSN] 1397-3142
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 7440-26-8 / Technetium; AYI8EX34EU / Creatinine
  •  go-up   go-down


90. Snoei J, Urbach H, Engels G, Fassunke J, von Lehe M, Becker AJ, Majores M: Genetic alterations of protein-o-mannosyltransferase-1 in glioneuronal and glial brain tumors with subarachnoid spread. Neuropathology; 2009 Apr;29(2):116-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations of protein-o-mannosyltransferase-1 in glioneuronal and glial brain tumors with subarachnoid spread.
  • Hypothesizing it as analogous in gliomas, we have performed a comprehensive polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis of the POMT1 gene in 41 brain tumor specimens.
  • Each specimen was subjected to laser capture microdissection analyses to dissect: (i) subarachnoid tumor components;.
  • (ii) deeply localized tumor areas; and (iii) histologically unaffected CNS fragments.
  • Exon 7 bore two sequence alterations, one 751C > T transition with amino acid exchange of arginine by tryptophane (Arg251Trp) (n = 12/41 in Tu vs n = 7/82 in Co) and a 752G > A transition with replacement of arginine by glutamine (Arg251Gln) (n = 3/41 in Tu vs n = 0/82 in Co) that were significantly increased in the tumor specimens compared to controls (P < 0.05).
  • We conclude that a significant increase of POMT1 missense mutations may indicate a functional role in neoplastic conditions in individual tumors.
  • Future studies will be important to evaluate a functional impact of POMT1 alterations in human brain tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Mannosyltransferases / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Microdissection. Middle Aged. Mutation, Missense. Polymerase Chain Reaction. Polymorphism, Genetic. Sequence Analysis, DNA. Subarachnoid Space. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647264.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] EC 2.4.1.- / Mannosyltransferases; EC 2.4.1.109 / protein O-mannosyltransferase
  •  go-up   go-down


91. Nieder C, Astner ST, Andratschke NH, Adam M: Disease presentation and outcome in very young patients with brain metastases from breast cancer. Tumori; 2008 Sep-Oct;94(5):691-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In patients with information available, tumors were poorly differentiated and metastatic to the axillary lymph nodes at primary diagnosis.
  • Whole-brain radiation therapy plus surgery or radiosurgery provided durable CNS control in most of the patients.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Breast Neoplasms / pathology. Breast Neoplasms / therapy
  • [MeSH-minor] Adult. Axilla. Cranial Irradiation. Female. Humans. Karnofsky Performance Status. Lymphatic Metastasis. Neoplasm Staging. Radiosurgery. Retrospective Studies. Treatment Outcome


92. Ligon KL, Fancy SP, Franklin RJ, Rowitch DH: Olig gene function in CNS development and disease. Glia; 2006 Jul;54(1):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olig gene function in CNS development and disease.
  • Olig1 and Olig2 encode basic helix-loop-helix (bHLH) transcription factors that are expressed in both the developing and mature vertebrate central nervous system.
  • Recent studies, however, reveal that in the fetal dorsal spinal cord and neural progenitor cells of the adult brain, Olig expression continues to mark, and may regulate, the formation of oligodendroglia.
  • Studies of Olig expression in human brain tumors and repair of demyelinating lesions suggest the possibility of additional functions in a variety of neurological diseases.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Cell Differentiation / genetics. Central Nervous System / embryology. Gene Expression Regulation, Developmental / genetics. Nerve Tissue Proteins / metabolism. Oligodendroglia / metabolism. Stem Cells / metabolism
  • [MeSH-minor] Animals. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / therapy. Cell Lineage / genetics. Demyelinating Diseases / genetics. Demyelinating Diseases / metabolism. Demyelinating Diseases / therapy. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16652341.001).
  • [ISSN] 0894-1491
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Nerve Tissue Proteins; 0 / OLIG1 protein, human
  • [Number-of-references] 106
  •  go-up   go-down


93. Reardon DA, Zalutsky MR, Bigner DD: Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther; 2007 May;7(5):675-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of these tumors recur at or adjacent to the site of origin, which indicates that failure to eradicate local tumor growth is a major factor contributing to poor outcome.
  • Malignant gliomas selectively express several factors that are not present on normal CNS tissue.
  • Regional administration of radiolabeled monoclonal antibodies targeting tumor-specific antigens expressed by malignant gliomas offers an innovative therapeutic strategy that has recently demonstrated encouraging antitumor activity and acceptable toxicity in clinical trials at a number of centers.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Radioimmunotherapy. Tenascin / immunology
  • [MeSH-minor] Administration, Topical. Adult. Humans

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17492931.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1-P50-CA108786-01; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Tenascin
  • [Number-of-references] 97
  •  go-up   go-down


94. McGuire CS, Sainani KL, Fisher PG: Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurg; 2009 Apr;110(4):725-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors analyzed a large, population-based cancer registry to examine the relationship of incidence to patient age, sex, race, and tumor location, and to determine incidence trends over the past 3 decades.
  • For children, the age at diagnosis differed significantly by tumor location, with the mean age for patients with infratentorial tumors calculated as 5 +/- 0.4 years; for supratentorial tumors it was 7.77 +/- 0.6 years, and for spinal lesions it was 12.16 +/- 0.8 years. (Values are expressed as the mean +/- standard error [SE].
  • ) Adults showed no difference in the mean age of incidence by location, although most tumors in this age group were spinal.
  • Ependymoma occurs within the CNS at distinct locations at different ages, consistent with hypotheses postulating distinct populations of radial glial stem cells within the CNS.
  • [MeSH-major] Brain Neoplasms / epidemiology. Ependymoma / epidemiology. Spinal Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. SEER Program. Sex Factors. United States / epidemiology


95. Santagata S, Hornick JL, Ligon KL: Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am J Surg Pathol; 2006 Dec;30(12):1613-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG.
  • Expression of NANOG has been detected in fetal germ cells and in gonadal germ cell tumors.
  • To assess the diagnostic utility of NANOG in central nervous system (CNS) germ cell tumors, we analyzed its expression by immunohistochemistry in a series of 12 CNS germinomas and compared its expression with other stem cell markers.
  • Strong nuclear expression of NANOG was demonstrated in >90% of the tumor cells in all cases.
  • NANOG was not detected in tumor types frequently considered in the differential diagnosis of CNS germinoma: pineoblastoma, primitive neuroectodermal tumors, medulloblastoma, lymphoma, pituitary adenoma, atypical teratoid/rhabdoid tumor, Langerhans cell histiocytosis, and gliomas.
  • These findings demonstrate that NANOG is a sensitive and specific marker of CNS germinoma.
  • Compared with other currently used markers, NANOG may have superior diagnostic characteristics and can facilitate identification of germinomas in minute surgical biopsies commonly obtained from these tumors.
  • These findings also suggest a potential biologic role for NANOG in maintenance of CNS germinoma.
  • [MeSH-major] Brain Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Germinoma / metabolism. Homeodomain Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Alkaline